405046128
  -OEChem-02172115172D

 57 60  0     1  0  0  0  0  0999 V2000
    7.3916    2.3112    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.8916   -0.2276    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.6517    1.0511    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.3884    1.7202    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.9794    3.1202    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.8916    0.7724    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    7.0826    1.3601    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    8.7006    1.3601    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    6.1316    1.0511    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3916    2.3112    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0256   -0.7276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.3948    1.7202    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0256   -1.7276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4374    1.4112    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3459    1.4112    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6942    2.0804    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1596   -2.2276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8916   -2.2276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5538    0.4331    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0890    2.0804    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9021    3.0585    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7431    1.7714    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.1596   -3.2276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8916   -3.2276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.5049    0.1241    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.0401    1.7714    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0256   -3.7276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.2480    0.7932    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1590    3.7276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0000    2.4405    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2079    3.4186    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4440    0.4909    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    6.6442    1.7986    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    9.1390    1.7986    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    5.6430    0.6694    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    6.4226    0.5037    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    6.8135   -0.1450    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    6.4150   -0.8353    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
   10.6859    2.2677    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    9.9063    2.1020    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.9488    1.0295    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    4.7284    0.8638    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    5.6226   -1.9176    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    8.4286   -1.9176    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
   11.0931    0.0182    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
   11.9601    2.6868    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    4.4918    3.2501    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    2.6142    1.1649    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    5.6226   -3.5376    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    8.4286   -3.5376    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
   12.6338   -0.4824    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
   13.5008    2.1862    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    7.0256   -4.3476    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
   13.8377    0.6016    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.2879    4.3341    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    1.4103    2.2489    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    1.7472    3.8335    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  7  1  0  0  0  0
  1 10  1  0  0  0  0
  6  2  1  6  0  0  0
  2 11  1  0  0  0  0
  8  3  1  6  0  0  0
  3 12  1  0  0  0  0
  4  9  1  0  0  0  0
  4 14  1  0  0  0  0
  5 10  2  0  0  0  0
  6  7  1  0  0  0  0
  6  8  1  0  0  0  0
  6 32  1  0  0  0  0
  7  9  1  1  0  0  0
  7 33  1  0  0  0  0
  8 10  1  0  0  0  0
  8 34  1  0  0  0  0
  9 35  1  0  0  0  0
  9 36  1  0  0  0  0
 11 13  1  0  0  0  0
 11 37  1  0  0  0  0
 11 38  1  0  0  0  0
 12 15  1  0  0  0  0
 12 39  1  0  0  0  0
 12 40  1  0  0  0  0
 13 17  2  0  0  0  0
 13 18  1  0  0  0  0
 14 16  1  0  0  0  0
 14 41  1  0  0  0  0
 14 42  1  0  0  0  0
 15 19  2  0  0  0  0
 15 20  1  0  0  0  0
 16 21  2  0  0  0  0
 16 22  1  0  0  0  0
 17 23  1  0  0  0  0
 17 43  1  0  0  0  0
 18 24  2  0  0  0  0
 18 44  1  0  0  0  0
 19 25  1  0  0  0  0
 19 45  1  0  0  0  0
 20 26  2  0  0  0  0
 20 46  1  0  0  0  0
 21 29  1  0  0  0  0
 21 47  1  0  0  0  0
 22 30  2  0  0  0  0
 22 48  1  0  0  0  0
 23 27  2  0  0  0  0
 23 49  1  0  0  0  0
 24 27  1  0  0  0  0
 24 50  1  0  0  0  0
 25 28  2  0  0  0  0
 25 51  1  0  0  0  0
 26 28  1  0  0  0  0
 26 52  1  0  0  0  0
 27 53  1  0  0  0  0
 28 54  1  0  0  0  0
 29 31  2  0  0  0  0
 29 55  1  0  0  0  0
 30 31  1  0  0  0  0
 30 56  1  0  0  0  0
 31 57  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_HEAVY_ATOM_COUNT>
31

> <PUBCHEM_ATOM_DEF_STEREO_COUNT>
3

> <PUBCHEM_ATOM_UDEF_STEREO_COUNT>
0

> <PUBCHEM_BOND_DEF_STEREO_COUNT>
0

> <PUBCHEM_BOND_UDEF_STEREO_COUNT>
0

> <PUBCHEM_ISOTOPIC_ATOM_COUNT>
0

> <PUBCHEM_COMPONENT_COUNT>
1

> <PUBCHEM_CACTVS_TAUTO_COUNT>
-1

> <PUBCHEM_SUBSTANCE_ID>
405046128

> <PUBCHEM_SUBSTANCE_VERSION>
1

> <PUBCHEM_EXT_DATASOURCE_NAME>
23909

> <PUBCHEM_EXT_DATASOURCE_REGID>
UPF06202

> <PUBCHEM_SUBSTANCE_COMMENT>
Shanghai Up-Fluorochem Co., Ltd. offers Remdesivir intermediates 2,3,5-Tri-O-benzyl-D-ribonolactone (CAS No. 55094-52-5) for your requirements of R&D, evaluation, pilots and commercial along with supportive technical package required for evaluation.
Remdesivir, also known as GS-5734, is a novel antiviral drug in the class of nucleotide analogs developed by Gilead Sciences. In February 2020 Remdesivir was being studied for experimental treatment of the emergent COVID-19 (novel coronavirus) disease.

> <PUBCHEM_SUBSTANCE_SYNONYM>
Anti-COVID-19 intermediate 2,3,5-Tri-O-benzyl-D-ribonolactone
Remdesivir intermediate
AntinCoV drug intermediate
Anti-nCoV drug intermediate
Anticovid-19 intermediate 2,3,5-Tri-O-benzyl-D-ribonolactone
Remedesivir intermediate
55094-52-5

> <PUBCHEM_GENERIC_REGISTRY_NAME>
55094-52-5

> <PUBCHEM_XREF_EXT_ID>
UPF06202

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.upfluorochem.com/

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://upfluorochem.com/product/goods_501.html

> <PUBCHEM_CID_ASSOCIATIONS>
11004289  1

> <PUBCHEM_COORDINATE_TYPE>
1
5
255

> <PUBCHEM_BONDANNOTATIONS>
13  17  8
13  18  8
15  19  8
15  20  8
16  21  8
16  22  8
17  23  8
18  24  8
19  25  8
6  2  6
20  26  8
21  29  8
22  30  8
23  27  8
24  27  8
25  28  8
26  28  8
29  31  8
8  3  6
30  31  8
7  9  5

$$$$
135652196
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
135652196

> <PUBCHEM_SUBSTANCE_VERSION>
9

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
667

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Synthetic analogue of bradykinin. There is some ambiguity in the literature and on online resources as to the exact chemical structure and stereochemistry of icatibant. Therefore, we have chosen not to include a chemical structure here. Users should note that there may not be agreement in the structures represented in the external links provided above.
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Icatibant has been approved to treat hereditary angiodema (HAE). The drug is under investigation for other conditions susceptible to bradykinin amelioration eg ACE inhibitor-induced angiodema, knee ostoearthritis and use during cardiopulmonary bypass surgery. Click here to link to Clinicaltrials.gov's records for this drug.COVID-19: Elevated levels of bradykinin have been detected in COVID-19 patients, and it is proposed that this 'bradykinin storm' might underlie many of the highly damaging symptoms of the infection [PMID:32633718][PMID:32359101]. By antagonising bradykinin signalling icatibant provides an exisitng therapeutic option to reduce the multi-system effects of bradykinin [PMID:32789513]. Direct destruction of ACE2 by SARS-CoV-2 binding likely participates in the loss of regulation of bradykinin levels, given ACE2's normal role in degrading vasodilatory des-Arg9-bradykinin [PMID:32818486].
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Although not approved for inflammation we have included icatibant in GtoImmuPdb as it was evaluated as a potential disease modifying agent in patients with osteoarthritis (OA) in Phase 2 clinical trial NCT00303056. However, development has not progressed, and no trial results appear to have been published. The rationale for testing a B2 receptor antagonist in OA is discussed in [PMID:23884024].

> <PUBCHEM_SUBSTANCE_SYNONYM>
icatibant
D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]BK
Firazyr
HOE 140
HOE140
GTPL667

> <PUBCHEM_XREF_EXT_ID>
667

> <PUBCHEM_PUBMED_ID>
32789513
32633718
32359101
10422787
23884024
9313952
8302267
9203620
10514288
8735629
10694205
32818486
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=667

$$$$
135650118
  -OEChem-02172115172D

 30 32  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  4  7  2  0  0  0  0
  7  8  1  0  0  0  0
  8  9  2  0  0  0  0
  9 10  1  0  0  0  0
  3 10  2  0  0  0  0
 10 11  1  0  0  0  0
 11 12  1  0  0  0  0
  9 13  1  0  0  0  0
 13 14  2  0  0  0  0
 14 15  1  0  0  0  0
 15 16  2  0  0  0  0
 16 17  1  0  0  0  0
 17 18  2  0  0  0  0
 17 19  1  0  0  0  0
 19 20  2  0  0  0  0
 13 20  1  0  0  0  0
 20 21  1  0  0  0  0
 21 22  1  0  0  0  0
 21 23  1  0  0  0  0
 23 24  1  0  0  0  0
  8 24  1  0  0  0  0
 21 25  1  0  0  0  0
 25 26  1  0  0  0  0
 26 27  2  0  0  0  0
 26 28  1  0  0  0  0
 16 29  1  0  0  0  0
 29 30  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
135650118

> <PUBCHEM_SUBSTANCE_VERSION>
12

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
2367

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Colchicine is a microtubule inhibitor. It is a methoxylated analogue of XD1 (colchicein).
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Colchicine is primarily used to treat gout. It can also be used to treat autoinflammatory conditions such as Behcet's syndrome. Colchicine was approved for use in combination with probenecid as early as 1961. Full US FDA approval was only granted for the single ingredient drug in 2009, although it had been marketed prior to this date without formal approval.SARS-CoV-2 and COVID-19: There are a number of clinical trials looking at the efficacy of colchicine as a therapy to help treat, and/or prevent the development of, severe symptoms in COVID-19 patients. Fifteen studies were registered on ClinicalTrials.gov on 17th July 2020 (click here to see them all). Colchicine is predicted to target inflammation and systemic clotting abnormalities that accompany COVID-19. This repositioning of colchicine is based both on the drug's established anti-inflammatory action, and on experimental evidence that colchicine-induced neutrophil depletion inhibits the release of the endogenous antimicrobial peptide alpha-defensin-1 (DEFA1) and reduces thrombus formation in experimental models [PMID:30705047].   Background: contact factors (such as kallikrein and FXIIa) connect inflammation to the activation of coagulation, via activated neutrophil-produced defensin alpha. DEFA1 acts to both stabilise fibrin and thrombus formation and impedes clot resolution by reducing fibrinolysis [PMID:30705047].
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Colchicine exhibits some inhibitory activity at the NLRP3 inflammasome [PMID:29352570].

> <PUBCHEM_SUBSTANCE_SYNONYM>
colchicine
N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[d]heptalen-7-yl]acetamide
Colcrys
methoxylated analogue of XD1
XD25
GTPL2367

> <PUBCHEM_XREF_EXT_ID>
2367

> <PUBCHEM_PUBMED_ID>
24272870
9681937
29352570
30705047
16504507
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2367

> <PUBCHEM_CID_ASSOCIATIONS>
6167  1

$$$$
405067330
  -OEChem-02172115172D

 27 28  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  2  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  2  0  0  0  0
  7  9  1  0  0  0  0
  3  9  2  0  0  0  0
  6 10  1  0  0  0  0
 10 11  1  0  0  0  0
 10 12  1  0  0  0  0
 12 13  1  0  0  0  0
 13 14  1  0  0  0  0
 13 15  1  0  0  0  0
 15 16  1  0  0  0  0
 15 17  1  0  0  0  0
 17 18  1  0  0  0  0
 10 17  1  0  0  0  0
 17 19  1  0  0  0  0
 15 20  1  0  0  0  0
 13 21  1  0  0  0  0
 21 22  1  0  0  0  0
 22 23  1  0  0  0  0
 23 24  2  0  0  0  0
 23 25  1  0  0  0  0
 25 26  1  0  0  0  0
 25 27  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
405067330

> <PUBCHEM_SUBSTANCE_VERSION>
4

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10737

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Molnupiravir (EIDD-2801, MK-4482) is a clinical stage, oral, broad-spectrum antiviral drug [PMID:32253226][PMID:32503817]. The proposed INN molnupiravir was released by the WHO in a special release to cover COVID-related therapeutics in October 2020 (Proposed INN: List 124- COVID-19). Chemically molnupiravir it is the isopropylester prodrug of the ribonucleoside analogue beta-D-N4-hydroxycytidine (EIDD-1931, or N-hydroxycytidine) [PMID:31645453][PMID:31945316]. EIDD-2801 was originally designed by Emory University scientists to inhibit replication of influenza virus. It has subsequently been tested for activity against other RNA viruses, including pandemic SARS-CoV-2, SARS-CoV and MERS-CoV [PMID:3071214]. EIDD-2801 is being progressed for COVID-19 in a collaboration between Ridgeback Biotherapeutics and Merck.
Clinical use: A first-in-human safety, tolerability and pharmacokinetics RCT investigating EIDD-2801 (in healthy volunteers) is underway in the UK (began in mid-April 2020) and plans are to begin recruiting US participants in late May 2020. Although Phase 1 safety results have not yet been published, Ridgeback Biotherapeutics have announced via press release (June 19, 2020) that EIDD-2801 is safe in humans at predicted therapeutic doses. At this time Ridgeback advised that they would launch two Phase 2 clinical trials in recently symptomatic, newly diagnosed COVID-19 patients (separate trials for newly hospitalised and newly diagnosed non-hospitalised patient groups) . These studies are already recruiting participants in the US, and equivalents are underway in the UK.

> <PUBCHEM_SUBSTANCE_SYNONYM>
molnupiravir
EIDD-2801
EIDD2801
MK-4482
MK4482
GTPL10737

> <PUBCHEM_XREF_EXT_ID>
10737

> <PUBCHEM_PUBMED_ID>
3071214
32253226
31945316
32503817
31645453

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10737

> <PUBCHEM_CID_ASSOCIATIONS>
145996610  1

$$$$
178103379
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
178103379

> <PUBCHEM_SUBSTANCE_VERSION>
12

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
6773

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Canakinumab targets interleukin-1beta [PMID:19169963].Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: Used to treat rheumatic diseases; familial cold autoinflammatory syndrome (FCAS) [PMID:19494217] and Muckle-Wells syndrome (MWS) in patients gt4 years of age, systemic juvenile idiopathic arthritis (sJIA) in patients gt2 years old [PMID:23252526], and adult-onset Still's disease.Unexpectedly, further analysis of data from the CANTOS cardiovascular disease trial revealed that IL-1beta inhibition significantly reduced the incidence of hip and knee replacements compared to those not treated with canakinumab, suggesting application of canakinumab as a large joint osteoarthritis therapeutic [PMID:32744862].SARS-CoV-2 and COVID-19: Canakinumab has been entered in to clinical trials that aim to determine its ability to combat the exaggerated immune response that drives cytokine storm and leads to tissue damage in the lung and other organs in patients with severe COVID-19.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: IL-1beta in cardiovascular disease: Canakinumab was the first anti-inflammatory agent to exhibit efficacy as a treatment for atherosclerosis. Results from the CANTOS trial (NCT01327846) showed that canakinumab (in high-risk patients; in addition to standard-of-care therapy) reduced the number of recurrent cardiovascular events that were recorded at 3-4 years follow-up [PMID:24864079][PMID:28845751]. These results confirmed that disruption of the IL-1beta inflammatory pathway was a valid therapeutic modality for cadiovascular disease prevention. It is informative to note that the largest reduction in cardiovascular mortality was observed in those patients who achieved the greatest reduction in the circulating inflammatory mediators IL-6 and CRP, which points to the importance of employing informed patient stratification in future studies.

> <PUBCHEM_SUBSTANCE_SYNONYM>
canakinumab
ACZ 885
ACZ885
Ilaris
GTPL6773

> <PUBCHEM_XREF_EXT_ID>
6773

> <PUBCHEM_PUBMED_ID>
28845751
24864079
23252526
19494217
19169963
32744862
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6773

$$$$
404859139
  -OEChem-02172115172D

 18 19  0     0  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 Br  0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  2  7  1  0  0  0  0
  5  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  2  0  0  0  0
 12 13  1  0  0  0  0
 12 14  1  0  0  0  0
 14 15  2  0  0  0  0
 15 16  1  0  0  0  0
 10 16  2  0  0  0  0
 16 17  1  0  0  0  0
 15 18  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
404859139

> <PUBCHEM_SUBSTANCE_VERSION>
1

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10692

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Ambroxol stimulates the synthesis and release of surfactant in the respiratory tract and acts as a mucoactive/expectorant drug. This action appears to be associated with ambroxol's regulation of glucosylceramide levels, via modulation of non-lysosomal glucosylceramidase (GCase) beta 2 (GBA2; Q9HCG7). Ambroxol is reported to act as a small molecule chaperone for GCase proteins that can increase the stability and function of mutant and wild-type GCases in in vitro and in vivo models [PMID:19578116][PMID:22682976][PMID:24574503][PMID:28216145][PMID:27859541], and in clinical trial subjects [PMID:27042680][PMID:23085429].  Ambroxol binds to nascent GCase proteins (at the enzyme active site) within the endoplasmic reticulum, and this action facilitates transport to the lysosome [PMID:23158495][PMID:22682976]. The acidic lysosomal environment provokes ambroxol dissassociation, leaving the enzyme free to function normally.
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: In some jurisdictions ambroxol is used as an orally delivered expectorant drug [PMID:30372367]. It is not yet authorised for use by the FDA or the EMA (but is approved by individual European agencies). Clinical evaluation as an expectorant are ongoing for future US approval.Ambroxol (as the hydrochloride) is being repurposed as a novel candidate for neurodegenerative diseases including Parkinson's disease (in particular in patients with defective beta-glucocerebrosidase GBA1 genes [PMID:26860875][PMID:19846850]) [PMID:24574503][PMID:30738426] and amyotrophic lateral sclerosis (ALS; motor neurone disease; MND) [PMID:31447678][PMID:18680446]. Click here to link to ClinicalTrials.gov's full list of ambroxol studies.  In July 2018, the EMA granted orphan designation for ambroxol hydrochloride to be used as a treatment for ALS/MND.

> <PUBCHEM_SUBSTANCE_SYNONYM>
ambroxol
4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol
GTPL10692

> <PUBCHEM_XREF_EXT_ID>
10692

> <PUBCHEM_PUBMED_ID>
28295625
24574503
31447678
30372367
18680446
30738426
19578116
22682976
28216145
27859541
27042680
23085429
26860875
19846850
23158495
31930374

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10692

> <PUBCHEM_CID_ASSOCIATIONS>
2132  1

$$$$
405067314
  -OEChem-02172115172D

 47 50  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  4  6  1  0  0  0  0
  4  7  1  0  0  0  0
  2  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  2  0  0  0  0
 10 11  1  0  0  0  0
 11 12  2  0  0  0  0
 12 13  1  0  0  0  0
 13 14  1  0  0  0  0
  9 14  1  0  0  0  0
 14 15  2  0  0  0  0
 13 16  1  0  0  0  0
 16 17  1  0  0  0  0
 16 18  1  0  0  0  0
 18 19  2  0  0  0  0
 18 20  1  0  0  0  0
 20 21  1  0  0  0  0
 21 22  1  0  0  0  0
 21 23  1  0  0  0  0
 23 24  1  0  0  0  0
 23 25  1  0  0  0  0
 25 26  2  0  0  0  0
 25 27  1  0  0  0  0
 27 28  1  0  0  0  0
 28 29  1  0  0  0  0
 29 30  1  0  0  0  0
 30 31  2  0  0  0  0
 31 32  1  0  0  0  0
 32 33  2  0  0  0  0
 33 34  1  0  0  0  0
 29 34  2  0  0  0  0
 23 35  1  0  0  0  0
 21 36  1  0  0  0  0
 36 37  1  0  0  0  0
 37 38  1  0  0  0  0
 37 39  1  0  0  0  0
 39 40  1  0  0  0  0
 40 41  1  0  0  0  0
 41 42  1  0  0  0  0
 37 42  1  0  0  0  0
 42 43  2  0  0  0  0
 16 44  1  0  0  0  0
 44 45  1  0  0  0  0
 45 46  1  0  0  0  0
 46 47  1  0  0  0  0
 45 47  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
405067314

> <PUBCHEM_SUBSTANCE_VERSION>
1

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10720

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Compound 13b is an inhibitor of SARS-CoV-2 main protease (Mpro) [PMID:32198291]. It is a derivative of the prevoiusly reported alpha-ketoamide inhibitor compound 11r [PMID: 32045235] [PMID:32045235]. Compound 13b has an enhanced plasma half-life compared to 11r, plus it exhibits substantial lung tropism and has shown suitability for inhalation-mediated administration.

> <PUBCHEM_SUBSTANCE_SYNONYM>
compound 13b [PMID: 32198291]
Tert-butyl  (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)-butan-2-yl)ami-no)-3-cyclopropyl-1-oxopropan-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate
GTPL10720

> <PUBCHEM_XREF_EXT_ID>
10720

> <PUBCHEM_PUBMED_ID>
32045235
32198291

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10720

> <PUBCHEM_CID_ASSOCIATIONS>
146018708  1

$$$$
252827462
  -OEChem-02172115172D

 54 57  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  4  6  1  0  0  0  0
  6  7  1  0  0  0  0
  6  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
  9 11  1  0  0  0  0
 11 12  1  0  0  0  0
 12 13  1  0  0  0  0
 13 14  2  0  0  0  0
 14 15  1  0  0  0  0
 15 16  2  0  0  0  0
 16 17  1  0  0  0  0
 12 17  2  0  0  0  0
  9 18  1  0  0  0  0
 18 19  1  0  0  0  0
 19 20  2  0  0  0  0
 19 21  1  0  0  0  0
 21 22  1  0  0  0  0
 21 23  1  0  0  0  0
 23 24  1  0  0  0  0
 23 25  1  0  0  0  0
 21 26  1  0  0  0  0
 26 27  1  0  0  0  0
 27 28  2  0  0  0  0
 27 29  1  0  0  0  0
 29 30  1  0  0  0  0
 30 31  1  0  0  0  0
 31 32  2  0  0  0  0
 32 33  1  0  0  0  0
 33 34  1  0  0  0  0
 34 35  2  0  0  0  0
 31 35  1  0  0  0  0
 34 36  1  0  0  0  0
 36 37  1  0  0  0  0
 36 38  1  0  0  0  0
 29 39  1  0  0  0  0
  6 40  1  0  0  0  0
  4 41  1  0  0  0  0
 41 42  1  0  0  0  0
 42 43  1  0  0  0  0
 43 44  2  0  0  0  0
 44 45  1  0  0  0  0
 45 46  2  0  0  0  0
 46 47  1  0  0  0  0
 42 47  2  0  0  0  0
  2 48  1  0  0  0  0
 48 49  1  0  0  0  0
 49 50  1  0  0  0  0
 50 51  2  0  0  0  0
 51 52  1  0  0  0  0
 52 53  2  0  0  0  0
 53 54  1  0  0  0  0
 50 54  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
252827462

> <PUBCHEM_SUBSTANCE_VERSION>
8

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
8804

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Ritonavir is an orally bioavailable antiviral that is generally administered in combination with other anti-HIV or anti-HCV drugs.
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_who - Substance is included in WHO Essential Medicines List.
Clinical use: Used to treat HIV+ve patients.

> <PUBCHEM_SUBSTANCE_SYNONYM>
ritonavir
RTV
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-di(phenyl)hexan-2-yl]carbamate
A-84538
ABBOTT-84538
ABT 538
ABT-538
Norvir
GTPL8804

> <PUBCHEM_XREF_EXT_ID>
8804

> <PUBCHEM_PUBMED_ID>
16248836
21030469
14657084
18285471

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804

> <PUBCHEM_CID_ASSOCIATIONS>
392622  1

$$$$
135651471
  -OEChem-02172115172D

 32 35  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  2  0  0  0  0
  3  5  1  0  0  0  0
  5  6  1  0  0  0  0
  5  7  1  0  0  0  0
  7  8  1  0  0  0  0
  7  9  1  0  0  0  0
  7 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  1  0  0  0  0
 11 13  1  0  0  0  0
  5 13  1  0  0  0  0
 13 14  1  0  0  0  0
 13 15  1  0  0  0  0
 15 16  1  0  0  0  0
 16 17  1  0  0  0  0
 16 18  1  0  0  0  0
 16 19  1  0  0  0  0
 19 20  1  0  0  0  0
 20 21  1  0  0  0  0
 11 20  1  0  0  0  0
 20 22  1  0  0  0  0
 22 23  1  0  0  0  0
 23 24  1  0  0  0  0
 24 25  2  0  0  0  0
 25 26  1  0  0  0  0
 26 27  2  0  0  0  0
 26 28  1  0  0  0  0
 28 29  2  0  0  0  0
 29 30  1  0  0  0  0
 19 30  1  0  0  0  0
 24 30  1  0  0  0  0
 30 31  1  0  0  0  0
 19 32  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
135651471

> <PUBCHEM_SUBSTANCE_VERSION>
11

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
2768

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Dexamethasone is a glucocorticoid receptor agonist with anti-inflammatory action.
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_who - Substance is included in WHO Essential Medicines List.
Clinical use: Dexamethasone may be administered by various routes to treat myriad inflammatory condtions, including inflammatory dermatoses, asthma, allergic or inflammatory nasal conditions, and nasal polyps, endocrine disorders and many more. Ozurdex has EMA authorisation as a treatment for macular edema and uveitis, and Neofordex can be used to treat multiple myeloma.SARS-CoV-2 infection (COVID-19): On June 16th 2020, it was reported that results from the UK recovery trial have shown a clear survival benefit of low-dose dexamethasone in COVID-19 patients with severe respiratory complications. It cut the risk of death by a third for patients on ventilators and by 20% for those on oxygen . This disclosure is preliminary, and pending peer review and publication.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).

> <PUBCHEM_SUBSTANCE_SYNONYM>
dexamethasone
(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
Decadron
desametasone
fluormethylprednisolone
GTPL2768

> <PUBCHEM_XREF_EXT_ID>
2768

> <PUBCHEM_PUBMED_ID>
8282004
9489701
10611474
10747884
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2768

> <PUBCHEM_CID_ASSOCIATIONS>
5743  1

$$$$
178101561
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
178101561

> <PUBCHEM_SUBSTANCE_VERSION>
19

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
4860

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Adalimumab is an anti-TNFalpha monoclonal antibody with immunosuppresive activity [PMID:10577977]. It was the first fully human monoclonal antibody drug approved by the FDA.Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.X-ray structures of the apo and TNFalpha-bound Fab fragment of adalimumab have been deposited to the RCSB Protein Data Bank (IDs 4NYL and 3WD5 respectively).Biosimilars:   NameTrade nameCompanyClinical PhaseIndicationsReferences  adalimumab-atto; ABP 501 Amjevita; AmgevitaAmgenApproved (2016 FDA, 2017 EMA)As per reference agent[PMID:28755394]    adalimumab-adbm; BI 695501CyltezoBoehringer IngelheimApproved (2017 FDA and EMA)As per reference agentnbsp    ZRC-3197ExemptiaCadila HealthcareApproved (2015 India)Rheumatoid arthritis[PMID:26176644]  adalimumab-bwwd; SB5HadlimaSamsung BioepisApproved (2019 FDA)As per reference agentnbsp  MSB11022Idacio; KromeyaFresenius KabiApproved (2019 EMA)As per reference agent BCD-057nbspBiocadPh 3 (NCT02762955)Plaque psoriasisnbsp    adalimumab-adaz; GP2017Hyrimoz; Hefiya; HalimatozSandozApproved (2018 EMA and FDA)As per reference agent [PMID:29962245]      M923nbspMomenta PharmaceuticalsPh 3 (NCT02581345)Plaque psoriasis, rheumatoid arthritis nbsp    adalimumab-fkjp; MYL-1401A; FKB327HulioMylan, Fujifilm Kyowa Kirin BiologicsApproved (2018 EMA, 2020 FDA)As per reference agent[PMID:28133772][PMID:32500668]            adalimumab-afzb; PF-06410293Abrilada; AmsparityPfizerApproved (2019 FDA, 2020 EMA)As per reference agent    IBI303nbspInnovent BiologicsPh 3 (NCT02893254)Active ankylosing spondylitis   AVT02Alvotech/DKSHPh 3 (NCT04453137)Plaque psoriasis, rheumatoid arthritis
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_who - Substance is included in WHO Essential Medicines List.
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: Used in the management of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and plaque psoriasis.In 2015 both the EMA and the FDA approved the use of adalimumab as a treatment for hidradenitis suppurativa, a chronic skin disease that causes abscesses and scarring on the skin.In July 2016, the FDA expanded adalimumab approval as the first non-corticosteroid drug available for use as a treatment for non-infectious intermediate, posterior and panuveitis (forms of autoimmune-driven inflammation of the uvea)- results from Phase 3 clinical trial NCT01138657 are published in [PMID:27602665]. The EMA marketing authorisation for adalimumab Trudexa was withdrawn at the request of the marketing authorisation holder.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Adalimumab is an anti-TNFalpha immunosuppresive drug.

> <PUBCHEM_SUBSTANCE_SYNONYM>
adalimumab
D2E7
Humira
GTPL4860

> <PUBCHEM_XREF_EXT_ID>
4860

> <PUBCHEM_PUBMED_ID>
28755394
27602665
12084005
12379628
10577977
24273556
26176644
28133772
32500668
29962245
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4860

$$$$
178103551
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
178103551

> <PUBCHEM_SUBSTANCE_VERSION>
7

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
6972

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: This drug is a recombinant, nonglycosylated form of the endogenous IL-1 receptor antagonist peptide with an additional methionine at the amino terminus compared to the endogenous peptide.
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Anakinra is used to treat the symptoms of moderate to severe rheumatoid arthritis and may also help slow the progress of the disease. This drug is usually tried after treatment with other arthritis medications has been unsuccessful.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Reduces the action of elevated IL-1 observed in rheumatoid arthritis.

> <PUBCHEM_SUBSTANCE_SYNONYM>
anakinra
antril
Kineret
GTPL6972

> <PUBCHEM_XREF_EXT_ID>
6972

> <PUBCHEM_PUBMED_ID>
1834644
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6972

$$$$
178103417
  -OEChem-02172115172D

 70 73  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  1  0  0  0  0
  7 12  1  0  0  0  0
 12 13  1  0  0  0  0
 11 14  1  0  0  0  0
 14 15  1  0  0  0  0
 15 16  2  0  0  0  0
 15 17  2  0  0  0  0
 15 18  1  0  0  0  0
 10 19  1  0  0  0  0
 19 20  1  0  0  0  0
 20 21  1  0  0  0  0
 21 22  1  0  0  0  0
 22 23  1  0  0  0  0
 23 24  1  0  0  0  0
 24 25  2  0  0  0  0
 24 26  2  0  0  0  0
 24 27  1  0  0  0  0
 21 28  1  0  0  0  0
 28 29  1  0  0  0  0
 29 30  1  0  0  0  0
 30 31  1  0  0  0  0
 20 31  1  0  0  0  0
 31 32  1  0  0  0  0
 30 33  1  0  0  0  0
 33 34  1  0  0  0  0
 34 35  2  0  0  0  0
 34 36  1  0  0  0  0
 29 37  1  0  0  0  0
  8 38  1  0  0  0  0
 38 39  2  0  0  0  0
 38 40  1  0  0  0  0
  5 41  1  0  0  0  0
 41 42  1  0  0  0  0
 42 43  1  0  0  0  0
  3 43  1  0  0  0  0
 43 44  1  0  0  0  0
 44 45  1  0  0  0  0
 45 46  1  0  0  0  0
 46 47  1  0  0  0  0
 47 48  1  0  0  0  0
 48 49  2  0  0  0  0
 48 50  1  0  0  0  0
 47 51  1  0  0  0  0
 51 52  1  0  0  0  0
 52 53  1  0  0  0  0
 45 53  1  0  0  0  0
 53 54  1  0  0  0  0
 54 55  1  0  0  0  0
 55 56  2  0  0  0  0
 55 57  2  0  0  0  0
 55 58  1  0  0  0  0
 52 59  1  0  0  0  0
 51 60  1  0  0  0  0
 42 61  1  0  0  0  0
 61 62  1  0  0  0  0
 62 63  2  0  0  0  0
 62 64  2  0  0  0  0
 62 65  1  0  0  0  0
 41 66  1  0  0  0  0
 66 67  1  0  0  0  0
 67 68  2  0  0  0  0
 67 69  2  0  0  0  0
 67 70  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178103417

> <PUBCHEM_SUBSTANCE_VERSION>
11

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
6811

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: A Low-Molecular-Weight Heparin antithrombin-III activator. It consists of fractionated material from pig mucosa but the PubChem structure represents the major form.Biosimilar drugs: The EMA approved enoxaparin biosimilars named Inhixa and Thorinane in 2016.
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_who - Substance is included in WHO Essential Medicines List.
Clinical use: Used to prevent and treat deep vein thrombosis or pulmonary embolism, and is given as a subcutaneous injection.SARS-CoV-2 and COVID-19: Based on scientific evidence that heparin is a potential target (attachment factor) for SARS-CoV [PMID:21887302] and other coronaviruses [PMID:16254381], and in reponse to the observed thrombotic pathology in COVID-19 patients, a clinical trial has been initiated in Italy (March 2020) to determine the efficacy of early treatment with enoxaparin in COVID-19 patients.

> <PUBCHEM_SUBSTANCE_SYNONYM>
enoxaparin
enoxaparin sodium
6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-3-[5-(6-carboxy-4,5-dihydroxy-3-sulfooxyoxan-2-yl)oxy-6-(hydroxymethyl)-3-(sulfoamino)-4-sulfooxyoxan-2-yl]oxy-4-hydroxy-5-sulfooxyoxane-2-carboxylic acid
Clexane
Lovenox
PK-10169
RP-54563
GTPL6811

> <PUBCHEM_XREF_EXT_ID>
6811

> <PUBCHEM_PUBMED_ID>
7667822
21887302
16254381

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6811

> <PUBCHEM_CID_ASSOCIATIONS>
772  1

$$$$
405067337
  -OEChem-02172115172D

 39 41  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  3  5  1  0  0  0  0
  5  6  2  0  0  0  0
  5  7  1  0  0  0  0
  7  8  2  0  0  0  0
  7  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  1  0  0  0  0
 10 12  1  0  0  0  0
  3 13  1  0  0  0  0
 13 14  1  0  0  0  0
 14 15  2  0  0  0  0
 14 16  1  0  0  0  0
 16 17  1  0  0  0  0
 16 18  1  0  0  0  0
 18 19  1  0  0  0  0
 19 20  2  0  0  0  0
 19 21  2  0  0  0  0
 19 22  1  0  0  0  0
 22 23  1  0  0  0  0
 23 24  1  0  0  0  0
 24 25  1  0  0  0  0
 23 25  1  0  0  0  0
 16 26  1  0  0  0  0
 26 27  1  0  0  0  0
 27 28  1  0  0  0  0
 27 29  1  0  0  0  0
 29 30  1  0  0  0  0
 29 31  1  0  0  0  0
 29 32  1  0  0  0  0
 27 33  1  0  0  0  0
 33 34  1  0  0  0  0
 34 35  2  0  0  0  0
 35 36  1  0  0  0  0
 36 37  2  0  0  0  0
 37 38  1  0  0  0  0
 33 38  2  0  0  0  0
 36 39  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
405067337

> <PUBCHEM_SUBSTANCE_VERSION>
2

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10746

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: VBY-825 is a reversible cysteine protease inhibitor with high potency against cathepsins B, L, S and V [PMID:20447439]. Human cysteinyl cathepsins are required for proteolytic processing of virally encoded proteins during infection [PMID:17553875][PMID:16081529][PMID:23236527], including a likely requirement for proper processing of the SARS-CoV-2 S protein within the endosome (activating its fusogenic acitivity) [PMID:16081529].     Experimental evidence indicates that VBY-825 has some antiviral activity against SARS-CoV-2 . In in vitro experiments VBY-825 inhibits SARS-CoV-2 entry. It does not inhibit the viral 3C-like protease (3CLpro) or papain-like protease (PLpro), which suggests that its antiviral activity is associated with inhibition of host proteases. In the oncology setting, a pre-clinical model of pancreatic islet cancer revealed that VBY-825 exhibits significant anti-tumour activity.

> <PUBCHEM_SUBSTANCE_SYNONYM>
VBY-825
(3S)-N-cyclopropyl-3-[[(2R)-3-(cyclopropylmethylsulfonyl)-2-[[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]amino]propanoyl]amino]-2-oxopentanamide
VBY825
GTPL10746

> <PUBCHEM_XREF_EXT_ID>
10746

> <PUBCHEM_PUBMED_ID>
16081529
17553875
23236527
20447439

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10746

> <PUBCHEM_CID_ASSOCIATIONS>
70945511  1

$$$$
249565679
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
249565679

> <PUBCHEM_SUBSTANCE_VERSION>
9

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
7999

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Sarilumab is a monoclonal antibody directed against the interleukin 6 receptor (IL6R). Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequence BLAST search using the heavy and light chain variable regions of sarilumab provides 100% matches to sequences covered by patent US7582298 , and  to the antibody with designation VQ8F11-21.
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: Sarilumab was granted FDA approval as a treatment for moderate to severe active RA in May 2017 (with EMA approval granted in June 2017), following evaluation in several clinical trials, either as a monotherapy (eg NCT02121210) or in combination with other drugs such as etanercept, methotrexate, tocilizumab and adalimumab. Click here to link to ClinicalTrials.gov's listing of Phase 3 sarilumab trials. A Phase 2 study for non-infectious uveitis (NCT01900431) has been completed, whereas a Phase 2 extension study (NCT01118728) for ankylosing spondylitis was terminated.SARS-CoV-2 and COVID-19: Sarilumab was evaluated for potential to reduce exaggerated inflammation in hospitalised patients with COVID-19 in the US.  The Phase 2/3 clinical trial (NCT04315298) did not meet its primary or secondary endpoints in these patients and the trial has been terminated. An Italian trial also failed to find mortality benefit [PMID:32620597]. Trials appear to be continuing in other countries.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: In clinical trial sarilumab significantly reduced the signs and symptoms of RA and improved physical function [PMID:28326189][PMID:27856432][PMID:27716324]. A notable side-effect is immune suppression leading to susceptibility to infection.

> <PUBCHEM_SUBSTANCE_SYNONYM>
sarilumab
Kevzara
REGN88
SAR153191
GTPL7999

> <PUBCHEM_XREF_EXT_ID>
7999

> <PUBCHEM_PUBMED_ID>
27856432
27716324
32620597
28326189
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7999

$$$$
135650261
  -OEChem-02172115172D

 22 22  0     0  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  2  0  0  0  0
 11 12  1  0  0  0  0
 12 13  2  0  0  0  0
 13 14  1  0  0  0  0
  9 14  2  0  0  0  0
 12 15  1  0  0  0  0
 15 16  1  0  0  0  0
 16 17  1  0  0  0  0
 17 18  1  0  0  0  0
 18 19  1  0  0  0  0
 17 20  1  0  0  0  0
 20 21  1  0  0  0  0
 17 22  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
135650261

> <PUBCHEM_SUBSTANCE_VERSION>
14

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
2407

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Fingolimod was the first approved oral therapy for multiple sclerosis.Fingolimod FTY720) is the prodrug of a S1P receptor agonist [PMID:15615513]. When fingolimod binds to S1P1R the complex is internalised and then degraded, so the drug acts as an indirect functional antagonist by preventing intracellular signalling. It acts as a lymphocyte migration inhibitor, promoting lymphocyte retention in lymphoid tissues, whilst preserving lymphocyte function [PMID:11923495]. Clinical efficacy results from modulation of S1P1 receptors. Adverse effects are thought to be caused by fingolimod's off-target effects on other S1P receptor subtypes.Selective S1P1R agonists are being developed and investigated for immunomodulatory/immunosuppresant potential.
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Used in the treatment of relapsing-remitting multiple sclerosis (MS) [PMID:18457527]. In May 2018, the FDA approved the use of fingolimod as a treatment for relapsing MS in pediatric patients. This is the first drug to be approved for treating MS in this patient group.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Selective S1P1R agonists are being developed and investigated for immunomodulatory/immunosuppresant potential.

> <PUBCHEM_SUBSTANCE_SYNONYM>
fingolimod
2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
FTY-720
FTY720
Gilenya
GTPL2407

> <PUBCHEM_XREF_EXT_ID>
2407

> <PUBCHEM_PUBMED_ID>
15615513
11923495
14747617
14732717
26751273
23145923
21520239
15707407
18457527
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407

> <PUBCHEM_CID_ASSOCIATIONS>
107970  1

$$$$
223366192
  -OEChem-02172115172D

 41 44  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  4  6  1  0  0  0  0
  6  7  2  0  0  0  0
  6  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
  9 11  1  0  0  0  0
 11 12  1  0  0  0  0
 12 13  1  0  0  0  0
 13 14  1  0  0  0  0
 13 15  1  0  0  0  0
 15 16  1  0  0  0  0
 16 17  1  0  0  0  0
  9 17  1  0  0  0  0
 17 18  2  0  0  0  0
 15 19  1  0  0  0  0
 19 20  2  0  0  0  0
 19 21  2  0  0  0  0
 19 22  1  0  0  0  0
 22 23  1  0  0  0  0
 23 24  2  0  0  0  0
 24 25  1  0  0  0  0
 25 26  2  0  0  0  0
 26 27  1  0  0  0  0
 22 27  2  0  0  0  0
 13 28  1  0  0  0  0
  4 29  1  0  0  0  0
 29 30  1  0  0  0  0
 30 31  2  0  0  0  0
 30 32  1  0  0  0  0
 32 33  2  0  0  0  0
 33 34  1  0  0  0  0
 34 35  1  0  0  0  0
 35 36  1  0  0  0  0
 32 36  1  0  0  0  0
 35 37  2  0  0  0  0
 37 38  1  0  0  0  0
 38 39  2  0  0  0  0
 39 40  1  0  0  0  0
 34 40  2  0  0  0  0
  2 41  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
223366192

> <PUBCHEM_SUBSTANCE_VERSION>
5

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
7862

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Relacatib is a cathepsin K inhibitor, developed by GlaxoSmithKline and selected for clinical development in osteoporosis.
Clinical use: A Phase I clinical trial was initiated in 2006 NCT00411190, but development has not progressed further.

> <PUBCHEM_SUBSTANCE_SYNONYM>
relacatib
N-[(2S)-4-methyl-1-[[(4S,7R)-7-methyl-3-oxo-1-pyridin-2-ylsulfonylazepan-4-yl]amino]-1-oxopentan-2-yl]-1-benzofuran-2-carboxamide
SB-462795
SB462795
GTPL7862

> <PUBCHEM_XREF_EXT_ID>
7862

> <PUBCHEM_PUBMED_ID>
18226527
20218623

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7862

> <PUBCHEM_CID_ASSOCIATIONS>
6918602  1

$$$$
178103048
  -OEChem-02172115172D

 29 30  0     0  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  2  0  0  0  0
  3  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  2  0  0  0  0
  7  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  2  0  0  0  0
 12 13  1  0  0  0  0
 13 14  2  0  0  0  0
 14 15  1  0  0  0  0
 10 15  2  0  0  0  0
 13 16  1  0  0  0  0
 16 17  1  0  0  0  0
 17 18  2  0  0  0  0
 17 19  1  0  0  0  0
 19 20  1  0  0  0  0
 20 21  2  0  0  0  0
 21 22  1  0  0  0  0
 22 23  2  0  0  0  0
 23 24  1  0  0  0  0
 19 24  2  0  0  0  0
 22 25  1  0  0  0  0
 25 26  2  0  0  0  0
 26 27  1  0  0  0  0
 26 28  1  0  0  0  0
  2 29  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178103048

> <PUBCHEM_SUBSTANCE_VERSION>
13

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
6432

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Publications and  data are also  linked to the camostat mesilate salt  (PubChem CID 5284360).  There is an active metabolite reported as FOY 251 but  this also maps to the mesylate salt (PubChem CID 130394), with the parent compound being  PubChem CID 130395SARS-CoV-2 and COVID-19: Inhibition of TMPRSS2 partially blocks entry of SARS-CoV-2 into Caco-2 cells [PMID:32142651], a result which indicates an opportunity for repurposing this already approved drug for COVID-19. Complete blockade of SARS-CoV-2 entry can be achieved by combined inhibition of TMPRSS2 (by camostat) and the endosomal cysteine proteases cathepsins B and L (by aloxistatin; E-64d). In August 2020 Edinburgh University, the CRUK's Centre for Drug Development and Latus Therapeutics began the Phase 2/3 SPIKE-1 trial (NCT04455815) of camostat in non-hospitalised CoV-2 positive patients, to determine if the drug can reduce the progression of COVID-19 symptoms- access CRUK's trial webpage here.
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Spectrum of indications in the literature including pancreatitis. This drug appears to have marketing approval only in Japan and South Korea.  More recent clnical indications include cystic fibrosis since prostasin is a channel-activating protease for the regulation  of epithelial sodium absorption [PMID:23412700] .SARS-CoV-2 and COVID-19: There a number of clinical trials around the world looking at camostat in COVID-19 patients. These trials are predominantly aimed to assess the ability of camostat to reduce the progression of COVID-19 symptoms in non-hospitalised, ambulatory or outpatients who have tested positive for SARS-CoV-2 infection.

> <PUBCHEM_SUBSTANCE_SYNONYM>
camostat
[4-[2-(2-dimethylamino-2-oxoethoxy)-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate
ONO-3403
GTPL6432

> <PUBCHEM_XREF_EXT_ID>
6432

> <PUBCHEM_PUBMED_ID>
23412700
32142651
22496216
27550352
7629790

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6432

> <PUBCHEM_CID_ASSOCIATIONS>
2536  1

$$$$
178102177
  -OEChem-02172115172D

 22 23  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  2  0  0  0  0
 11 12  1  0  0  0  0
 12 13  2  0  0  0  0
 13 14  1  0  0  0  0
  9 14  2  0  0  0  0
 14 15  1  0  0  0  0
 15 16  2  0  0  0  0
 16 17  1  0  0  0  0
 17 18  2  0  0  0  0
 13 18  1  0  0  0  0
 17 19  1  0  0  0  0
  7 20  1  0  0  0  0
  3 21  1  0  0  0  0
 21 22  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178102177

> <PUBCHEM_SUBSTANCE_VERSION>
14

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
5535

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Chloroquine is a 4-aminoquinoline and used primarily as an antimalarial drug.  The approved drug is a racemic mixture and we show the chemical structure without stereochemistry to represent the mixture. The non-isomeric structure is also represented in the PubChem, ChEMBL and ChEBI entries listed in the links table below, while the two enantiomers forming the racemate are represented by PubChem CID 444810 and PubChem CID 639540. The PDB entry listed in the links table is for (R)-chloroquine. Marketed formulations may contain chloroquine phosphate (PubChem CID 64927).The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_who - Substance is included in WHO Essential Medicines List.
Clinical use: Chloroquine is one of the antimalarials listed in the World Health Organisation's 21st Essential Medicines List (2019), with its recommended use restricted to the prevention and treatment of P. vivax infection in areas where resistance has not yet developed.    It is also used off-label for other conditions/diseases, including treatment of autoimmune disorders (rheumatoid arthritis and lupus erythematosus), as an antiretroviral (HIV-1/AIDS and chikungunya fever) and as a radiosensitizing/chemosensitizing agent benefitting cancer therapies.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Chloroquine is authorised in the UK for the treatment of the autoimmune disorders rheumatoid arthritis and discoid and systemic lupus erythematosus.
gtopdb_malaria - Substance is curated in IUPHAR/MMV Guide to Malaria Pharmacology (GtoMPdb).
GtoMPdb Comments: Chloroquine is authorised in the UK for the treatment of the autoimmune disorders rheumatoid arthritis and discoid and systemic lupus erythematosus.

> <PUBCHEM_SUBSTANCE_SYNONYM>
chloroquine
N'-(7-chloroquinolin-4-yl)-N,N-diethylpentane-1,4-diamine
Aralen
chloraquine
Malaquin
GTPL5535

> <PUBCHEM_XREF_EXT_ID>
5535

> <PUBCHEM_PUBMED_ID>
22363211
20004959
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535

> <PUBCHEM_CID_ASSOCIATIONS>
2719  1

$$$$
178103377
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
178103377

> <PUBCHEM_SUBSTANCE_VERSION>
15

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
6771

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Vascular endothelial growth factor A inhibitor.Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB  record.Biosimilars: Bevacizumab-awwb (Mvasi, developed by Amgen) was the first bevacizumab biosimilar to be FDA approved (September 2017). Approval covers treatment of a range of cancers, including certain colorectal, lung, brain, kidney and cervical cancers.Pfizer's biosimilar (PF-06439535; bevacizumab-bvzr; trade name Zirabev) received EMA and FDA marketing authorisations in 2019. It is indicated for specified colorectal, breast, renal, lung, and cervical cancers by the EMA, with approval for breast cancers replaced by approval for recurrent glioblastoma under the FDA authorisation.  SB8 is in development by Samsung Bioepis (Phase 3 NCT02754882).CBT124 (Cipla BioTech; NCT02879097) is in Phase 3 development.
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_who - Substance is included in WHO Essential Medicines List.
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: Used as part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer. In August 2014 the US FDA granted additional approval for metastatic cervical cancer. In November 2014, FDA approval was extended to include a combination therapy of bevacizumab plus chemotherapy (paclitaxel, pegylated liposomal doxorubicin or topotecan)  for platinum-resistant, recurrent ovarian cancer (based on findings from the Phase 3 AURELIA clinical trial NCT00976911). Additional Phase 2 clinical trial results are provided in [PMID:12890841].   In June 2018, FDA approval was further expanded to include the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, in patients with stage III or IV disease, and to be used after initial surgical resection  [PMID:26487588].   Clinical trials evaluating bevacizumab in combination with the immune checkpoint inhibitors ipilimumab (anti-CTLA4) or nivolumab (anti-PD-1) in advanced solid malignancies are underway (for example NCT01950390- Phase 2 stage III-IV melanoma; NCT01454102- Phase 1 stage IIIB/IV non-small cell lung cancer).A re-engineered version of bevacizumab with a different glycosylation profile (bevacizumab beta, ABP 215) is in Phase 3 clinical trial for metastatic non-small cell lung cancers (NSCLC), This trial, NCT01966003 is comparing bevacizumab beta vs. the original bevacizumab,Bevacizumab (Avastin) is sometimes prescribed 'off-label' as a therapy for wet age-related macular degeneration (AMD), as an alternative to ranibizumab (Lucentis) and aflibercept (Eylea).SARS-CoV-2 and COVID-19: Bevacizumab has been entered into clinical trials in patients with COVID-19, to determine if suppression of vascular permeability will reduce pulmonary edema in severe/critical COVID-19 patients.

> <PUBCHEM_SUBSTANCE_SYNONYM>
bevacizumab
Avastin
rhuMAb-VEGF
GTPL6771

> <PUBCHEM_XREF_EXT_ID>
6771

> <PUBCHEM_PUBMED_ID>
12890841
12662141
26487588

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6771

$$$$
187051772
  -OEChem-02172115172D

 45 50  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  3  5  1  0  0  0  0
  2  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  2  0  0  0  0
  8 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  1  0  0  0  0
 12 13  1  0  0  0  0
 12 14  1  0  0  0  0
 14 15  1  0  0  0  0
 15 16  1  0  0  0  0
 10 15  1  0  0  0  0
 15 17  1  0  0  0  0
 17 18  1  0  0  0  0
 18 19  1  0  0  0  0
 18 20  1  0  0  0  0
 10 20  1  0  0  0  0
 20 21  1  0  0  0  0
 20 22  1  0  0  0  0
 22 23  1  0  0  0  0
 23 24  1  0  0  0  0
 23 25  1  0  0  0  0
 23 26  1  0  0  0  0
 26 27  1  0  0  0  0
 26 28  1  0  0  0  0
 28 29  1  0  0  0  0
 18 28  1  0  0  0  0
 28 30  1  0  0  0  0
 30 31  1  0  0  0  0
 31 32  1  0  0  0  0
 32 33  2  0  0  0  0
 33 34  1  0  0  0  0
 34 35  2  0  0  0  0
 34 36  1  0  0  0  0
 36 37  2  0  0  0  0
 37 38  1  0  0  0  0
 26 38  1  0  0  0  0
 32 38  1  0  0  0  0
 38 39  1  0  0  0  0
 12 40  1  0  0  0  0
 40 41  1  0  0  0  0
 41 42  1  0  0  0  0
 42 43  1  0  0  0  0
 43 44  1  0  0  0  0
 44 45  1  0  0  0  0
 40 45  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
187051772

> <PUBCHEM_SUBSTANCE_VERSION>
11

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
7469

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Ciclesonide is a prodrug. The active metabolite is desisobutyrylciclesonide (PubChem CID 6918281). It is a clinically used inhalation corticosteroid/glucocorticoid drug.
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Ciclesonide is an inhalation glucocorticoid. It is approved to treat inflammatory/obstructive airway diseases such as persistent asthma.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).

> <PUBCHEM_SUBSTANCE_SYNONYM>
ciclesonide
Alvesco
Omnaris
RPR-251526
GTPL7469

> <PUBCHEM_XREF_EXT_ID>
7469

> <PUBCHEM_PUBMED_ID>
15878996
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7469

> <PUBCHEM_CID_ASSOCIATIONS>
6918155  1

$$$$
187051836
  -OEChem-02172115172D

 57 61  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  4  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  2  0  0  0  0
  9 10  1  0  0  0  0
 10 11  2  0  0  0  0
 11 12  1  0  0  0  0
  7 12  2  0  0  0  0
  4 13  1  0  0  0  0
 13 14  1  0  0  0  0
 14 15  1  0  0  0  0
 15 16  1  0  0  0  0
 15 17  1  0  0  0  0
 17 18  1  0  0  0  0
 18 19  1  0  0  0  0
 19 20  2  0  0  0  0
 20 21  1  0  0  0  0
 21 22  2  0  0  0  0
 22 23  1  0  0  0  0
 18 23  2  0  0  0  0
 15 24  1  0  0  0  0
 24 25  1  0  0  0  0
 25 26  2  0  0  0  0
 25 27  1  0  0  0  0
 27 28  1  0  0  0  0
 27 29  1  0  0  0  0
 29 30  1  0  0  0  0
 30 31  2  0  0  0  0
 30 32  1  0  0  0  0
 32 33  1  0  0  0  0
 33 34  1  0  0  0  0
 34 35  2  0  0  0  0
 35 36  1  0  0  0  0
 36 37  1  0  0  0  0
 37 38  2  0  0  0  0
 34 38  1  0  0  0  0
 37 39  1  0  0  0  0
 39 40  1  0  0  0  0
 39 41  1  0  0  0  0
 32 42  1  0  0  0  0
 27 43  1  0  0  0  0
 43 44  1  0  0  0  0
 44 45  1  0  0  0  0
 45 46  1  0  0  0  0
 46 47  1  0  0  0  0
 47 48  1  0  0  0  0
 48 49  1  0  0  0  0
 49 50  1  0  0  0  0
 45 50  1  0  0  0  0
  2 51  1  0  0  0  0
 51 52  1  0  0  0  0
 52 53  1  0  0  0  0
 53 54  2  0  0  0  0
 54 55  1  0  0  0  0
 55 56  2  0  0  0  0
 56 57  1  0  0  0  0
 53 57  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
187051836

> <PUBCHEM_SUBSTANCE_VERSION>
8

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
7535

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: This compound is approved as a component of the so-called 'Quad pill' (Stribild), an anti-HIV therapy which contains cobicistat, elvitegravir, emtricitabine, and tenofovir.
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Used as a pharmacokinetic booster, to enhance systemic exposure to anti-HIV drugs.

> <PUBCHEM_SUBSTANCE_SYNONYM>
cobicistat
1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
GS-9350
GTPL7535

> <PUBCHEM_XREF_EXT_ID>
7535

> <PUBCHEM_PUBMED_ID>
24900196
20043009
22850510

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535

> <PUBCHEM_CID_ASSOCIATIONS>
25151504  1

$$$$
310264716
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
310264716

> <PUBCHEM_SUBSTANCE_VERSION>
7

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
8935

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Lenzilumab is a fully human IgG1kappa moncolonal antibody targeting granulocyte-macrophage colony-stimulating factor (GM-CSF), being investigated for its immunomodulatory potential.Peptide sequences for this antibody are available from its IMGT/mAb-DB record.BLAST peptide searches using the variable regions of the heavy and light chains of the antibody reveal exact matches with sequences submitted with patent US8075885 B2 .
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: Lenzilumab has completed Phase 2 clinical trial for uncontrolled asthma, whereas a Phase 2 study in patients with inadequately controlled rheumatoid arthritis has been terminated. A Phase 1 trial in patients with previously treated chronic myelomonocytic leukemia (CMML) is ongoing [PMID:23632888].SARS-CoV-2 and COVID-19:Lenzilumab has been entered into clinical trial to determine if blocking GM-CSF signalling can help to alleviate the immune-mediated cytokine release syndrome in patients with severe or critical COVID-19 pneumonia. The aim would be reduce the time to recovery in hospitalised patients.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).

> <PUBCHEM_SUBSTANCE_SYNONYM>
lenzilumab
KB-003
KB003
GTPL8935

> <PUBCHEM_XREF_EXT_ID>
8935

> <PUBCHEM_PUBMED_ID>
23632888
25748625
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8935

$$$$
375973224
  -OEChem-02172115172D

 33 35  0     0  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0  0  0  0
  2  3  1  0  0  0  0
  3  4  2  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  2  0  0  0  0
  7  8  1  0  0  0  0
  8  9  2  0  0  0  0
  5  9  1  0  0  0  0
  8 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  2  0  0  0  0
 12 13  1  0  0  0  0
 13 14  2  0  0  0  0
 14 15  1  0  0  0  0
 10 15  2  0  0  0  0
 14 16  1  0  0  0  0
 16 17  1  0  0  0  0
 16 18  1  0  0  0  0
 16 19  1  0  0  0  0
 12 20  1  0  0  0  0
 20 21  1  0  0  0  0
 20 22  1  0  0  0  0
 20 23  1  0  0  0  0
  2 24  1  0  0  0  0
 24 25  1  0  0  0  0
 25 26  1  0  0  0  0
 26 27  1  0  0  0  0
 27 28  2  0  0  0  0
 28 29  1  0  0  0  0
 29 30  2  0  0  0  0
 30 31  1  0  0  0  0
 26 31  2  0  0  0  0
  3 32  1  0  0  0  0
  4 33  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
375973224

> <PUBCHEM_SUBSTANCE_VERSION>
6

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10036

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Selinexor (KPT-330) is an inhibitor of the nuclear export protein XPO1 (a.k.a. exportin 1) that is being developed as an anti-neoplastic agent by Karyopharm Therapeutics. It is a first-in-class inhibitor that exploits a novel mechanism of action compared to existing chemotherapeutics [PMID:25316614][PMID:25281264][PMID:31231778]. The chemical structure is claimed in patent WO2013019561A1 (as compound 70) .
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: The first FDA approval of selinexor (KPT-330) was granted in July 2019, as a treatment for relapsed/refractory multiple myeloma in patients who have received at least four prior therapies (refractory to getwo proteasome inhibitors, getwo immunomodulatory agents, and an anti-CD38 monoclonal antibody).Clinical trials in additional cancers are ongoing. Click here to view the full list of KPT-330 studies at ClinicalTrials.gov. The most advance trials are Phase 3 studies in endometrial cancer (NCT03555422) and dedifferentiated (advanced) liposarcoma (NCT02606461). In June 2020, the FDA granted accelerated approval for the use of selnexor for relapsed/refractory diffuse large B-cell lymphoma (DLBCL, including that arising from follicular lymphoma) after at least 2 lines of systemic therapy.       Because of its novel mechanism of action selinexor is an ideal candidate for use in combination with (or following failure of) other chemotherapeutics such as proteasome inhibitors, kinase inhibitors and checkpoint inhibitors [PMID:28852098][PMID:29340049]. It has also been discovered that treatment with selinexor can re-sensitize cancer cells to previous treatments to which they had become refractory [PMID:29707241].Repurposing for COVID-19: SINE compounds like selinexor have been shown to disrupt the replication of multiple viruses in vitro and in vivo and to mediate anti-inflammatory and anti-viral effects in animal models [PMID:30332435]. In respect of SARS-CoV-2, SINE compounds have been reported to exhibit potential to interfere with interactions between viral proteins and key host proteins [PMID:32353859]. Based on this in vitro observation, low-dose selinexor has been advanced to Phase 2 investigation in patients with severe COVID-19 (NCT04349098).
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Selinexor (KPT-330) has been found to reduce pro-inflammatory cytokine production (TNF-alpha and IL-6), decrease macrophage and PMN subpopulations in the peritoneal cavity, and thereby protect against sepsis in a LPS-induced sepsis model in vivo [PMID:30064906].

> <PUBCHEM_SUBSTANCE_SYNONYM>
selinexor
(Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N'-pyrazin-2-ylprop-2-enehydrazide
compound 70 [WO2013019561A1]
KPT-330
KPT330
Xpovio
GTPL10036

> <PUBCHEM_XREF_EXT_ID>
10036

> <PUBCHEM_PUBMED_ID>
32353859
30332435
25316614
25281264
30064906
9368044
29707241
29340049
28852098
31231778
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10036

> <PUBCHEM_CID_ASSOCIATIONS>
71481097  1

$$$$
405067328
  -OEChem-02172115172D

 22 23  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  3  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  6  8  1  0  0  0  0
  8  9  1  0  0  0  0
  8 10  1  0  0  0  0
 10 11  1  0  0  0  0
  3 10  1  0  0  0  0
 10 12  1  0  0  0  0
  8 13  1  0  0  0  0
  6 14  1  0  0  0  0
 14 15  1  0  0  0  0
 15 16  2  0  0  0  0
 16 17  1  0  0  0  0
 17 18  2  0  0  0  0
 18 19  1  0  0  0  0
 14 19  1  0  0  0  0
 19 20  2  0  0  0  0
 17 21  1  0  0  0  0
 21 22  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
405067328

> <PUBCHEM_SUBSTANCE_VERSION>
2

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10735

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Preliminary evidence form a BioRxiv preprint indicates that the ribonucleoside analog beta-D-N4-hydroxycytidine (NHC, EIDD-1931) has broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs. The potency of the NHC ester prodrug (molnupiravir) against multiple coronaviruses, its therapeutic efficacy, and oral bioavailability in vivo, all highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses.

> <PUBCHEM_SUBSTANCE_SYNONYM>
beta-D-N4-hydroxycytidine
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hydroxyamino)pyrimidin-2-one
EIDD-1931
NHC
GTPL10735

> <PUBCHEM_XREF_EXT_ID>
10735

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10735

> <PUBCHEM_CID_ASSOCIATIONS>
197020  1

$$$$
404859153
  -OEChem-02172115172D

 32 34  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 P   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 P   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 I   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  2  4  1  0  0  0  0
  4  5  1  0  0  0  0
  4  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  2  0  0  0  0
  8 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  2  0  0  0  0
 11 13  1  0  0  0  0
 11 14  1  0  0  0  0
  8 15  1  0  0  0  0
  4 16  1  0  0  0  0
 16 17  1  0  0  0  0
 17 18  1  0  0  0  0
 17 19  1  0  0  0  0
 19 20  1  0  0  0  0
  2 19  1  0  0  0  0
 19 21  1  0  0  0  0
 17 22  1  0  0  0  0
 22 23  1  0  0  0  0
 23 24  2  0  0  0  0
 24 25  1  0  0  0  0
 25 26  1  0  0  0  0
 22 26  1  0  0  0  0
 26 27  2  0  0  0  0
 27 28  1  0  0  0  0
 28 29  1  0  0  0  0
 28 30  2  0  0  0  0
 30 31  1  0  0  0  0
 25 31  2  0  0  0  0
 31 32  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
404859153

> <PUBCHEM_SUBSTANCE_VERSION>
1

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10706

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Compound 15 is a small molecule, ADP analogue-based  CD73 (ecto-5'-nucleotidase) inhibitor [PMID:32045236]. Mechanisms to inhibit CD73 activity are being exploited for immuno-oncology potential, and are exemplified by the progress of the anti-CD73 monoclonal oleclumab and the small molecule inhibitor AB680 into clinical trials as treatments for advanced solid tumours.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: CD73 hydrolyzes AMP to adenosine, and thus regulates the extracellular concentration of adenosine. It is expressed by lymphocytes, endothelial, and epithelial cells, and expression is upregulated under hypoxic or inflammatory conditions, and in various cancers. Elevated CD73 in tumours leads to increased levels of adenosine which impairs antitumour immunity and promotes tumour growth and metastasis. Mechanisms to inhibit CD73 activity are being exploited for immuno-oncology potential, and are exemplified by the progress of the anti-CD73 monoclonal oleclumab and the small molecule inhibitor AB680 into clinical trials as treatments for solid tumours.

> <PUBCHEM_SUBSTANCE_SYNONYM>
compound 15 [PMID: 32045236]
2-Iodoadenosine-5'-O-[(phosphonomethyl)phosphonic Acid]
GTPL10706

> <PUBCHEM_XREF_EXT_ID>
10706

> <PUBCHEM_PUBMED_ID>
32045236
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10706

> <PUBCHEM_CID_ASSOCIATIONS>
145996542  1

$$$$
178103448
  -OEChem-02172115172D

 21 22  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  3  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  6  8  1  0  0  0  0
  8  9  1  0  0  0  0
  8 10  1  0  0  0  0
 10 11  1  0  0  0  0
  3 10  1  0  0  0  0
 10 12  1  0  0  0  0
  8 13  1  0  0  0  0
  6 14  1  0  0  0  0
 14 15  1  0  0  0  0
 15 16  2  0  0  0  0
 16 17  1  0  0  0  0
 17 18  2  0  0  0  0
 14 18  1  0  0  0  0
 17 19  1  0  0  0  0
 19 20  2  0  0  0  0
 19 21  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178103448

> <PUBCHEM_SUBSTANCE_VERSION>
9

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
6842

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Inhibits inosine-5'-monophosphate dehydrogenase 1 and RNA and also inhibits hepatitis C virus RNA-dependent RNA polymerase (NS5B).
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_who - Substance is included in WHO Essential Medicines List.
Clinical use: A nucleoside antimetabolite antiviral agent blocking nucleic acid synthesis used against several RNA and DNA viruses. Used orally (alongside interferon drugs) to treat hepatitis C and in an aerosol form to treat respiratory syncytial virus-related diseases in children.

> <PUBCHEM_SUBSTANCE_SYNONYM>
ribavirin
RBV
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
Copegus
Rebetol
ribofluranosyl carboxamide
Virazole
GTPL6842

> <PUBCHEM_XREF_EXT_ID>
6842

> <PUBCHEM_PUBMED_ID>
25011570
32633831
32284326
22555152
32660307

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842

> <PUBCHEM_CID_ASSOCIATIONS>
37542  1

$$$$
178103944
  -OEChem-02172115172D

 33 35  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  2  0  0  0  0
  6  7  1  0  0  0  0
  7  8  2  0  0  0  0
  8  9  1  0  0  0  0
  4  9  2  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
  6 12  1  0  0  0  0
 12 13  1  0  0  0  0
 12 14  1  0  0  0  0
 14 15  1  0  0  0  0
 15 16  2  0  0  0  0
 15 17  1  0  0  0  0
 17 18  1  0  0  0  0
 18 19  1  0  0  0  0
 14 19  1  0  0  0  0
 19 20  2  0  0  0  0
 18 21  2  0  0  0  0
 21 22  1  0  0  0  0
 22 23  2  0  0  0  0
 23 24  1  0  0  0  0
 17 24  2  0  0  0  0
 21 25  1  0  0  0  0
 25 26  1  0  0  0  0
 26 27  2  0  0  0  0
 26 28  1  0  0  0  0
 12 29  1  0  0  0  0
 29 30  1  0  0  0  0
 30 31  2  0  0  0  0
 30 32  2  0  0  0  0
 30 33  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178103944

> <PUBCHEM_SUBSTANCE_VERSION>
10

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
7372

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Apremilast is an oral small molecule phosphodiesterase 4 (PDE4) inhibitor [PMID:19256507][PMID:22305044] (additional comment in [PMID:23680197]). It is selective for PDE4 over other PDE isozymes, but non-selective over PDE4 isoforms [PMID:24882690].
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Apremilast is approved to treat psoriatic arthritis (PsA). This drug is also in clinical trial as a potential treatment for several other inflammatory conditions. View a list of these trials at ClinicalTrials.gov. In the US and EU, apremilast has been granted orphan desigantion for the treatment of Behccedilet disease, an auto-immune disease which damages blood vessels and causes sores on mucosal membranes and occular and vascular inflammation.In September 2014, the US FDA granted approval for the treatment of patients with moderate to severe plaque psoriasis, making Otezla the first and only PDE4 inhibitor available for this indication.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Apremilast is an orally active pan-PDE4 inhibitor [PMID:24882690]. It has regulatory effects on innate immunity, principally by reducing TNF-alpha production from leukocytes. Apremilast also reduces nitric oxide synthase and IL-23 levels and increases IL-10 levels [PMID:22257911].

> <PUBCHEM_SUBSTANCE_SYNONYM>
apremilast
N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide
CC-10004
Otezla
GTPL7372

> <PUBCHEM_XREF_EXT_ID>
7372

> <PUBCHEM_PUBMED_ID>
22257911
23680197
22305044
19256507
24882690
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7372

> <PUBCHEM_CID_ASSOCIATIONS>
11561674  1

$$$$
178103484
  -OEChem-02172115172D

 75 77  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  2  0  0  0  0
  4  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  7  9  1  0  0  0  0
  9 10  2  0  0  0  0
  9 11  1  0  0  0  0
 11 12  1  0  0  0  0
 12 13  1  0  0  0  0
 12 14  1  0  0  0  0
 14 15  2  0  0  0  0
 14 16  1  0  0  0  0
 16 17  1  0  0  0  0
 17 18  1  0  0  0  0
 17 19  1  0  0  0  0
 19 20  2  0  0  0  0
 19 21  1  0  0  0  0
 21 22  1  0  0  0  0
 22 23  1  0  0  0  0
 22 24  1  0  0  0  0
 24 25  2  0  0  0  0
 24 26  1  0  0  0  0
 26 27  1  0  0  0  0
 27 28  1  0  0  0  0
 27 29  1  0  0  0  0
 29 30  2  0  0  0  0
 29 31  1  0  0  0  0
 31 32  1  0  0  0  0
 32 33  1  0  0  0  0
 33 34  1  0  0  0  0
 34 35  1  0  0  0  0
 35 36  1  0  0  0  0
 31 35  1  0  0  0  0
 35 37  1  0  0  0  0
 37 38  2  0  0  0  0
 37 39  1  0  0  0  0
 39 40  1  0  0  0  0
 40 41  1  0  0  0  0
 40 42  1  0  0  0  0
 42 43  2  0  0  0  0
 42 44  1  0  0  0  0
 40 45  1  0  0  0  0
 27 46  1  0  0  0  0
 46 47  1  0  0  0  0
 47 48  1  0  0  0  0
 48 49  1  0  0  0  0
 48 50  1  0  0  0  0
 50 51  2  0  0  0  0
 51 52  1  0  0  0  0
 47 52  2  0  0  0  0
 22 53  1  0  0  0  0
 53 54  1  0  0  0  0
 53 55  1  0  0  0  0
 55 56  1  0  0  0  0
 53 57  1  0  0  0  0
 17 58  1  0  0  0  0
 58 59  1  0  0  0  0
 59 60  1  0  0  0  0
 60 61  2  0  0  0  0
 61 62  1  0  0  0  0
 62 63  2  0  0  0  0
 63 64  1  0  0  0  0
 59 64  2  0  0  0  0
 62 65  1  0  0  0  0
 12 66  1  0  0  0  0
 66 67  1  0  0  0  0
 66 68  1  0  0  0  0
  7 69  1  0  0  0  0
 69 70  1  0  0  0  0
 70 71  1  0  0  0  0
 71 72  1  0  0  0  0
 72 73  2  0  0  0  0
 73 74  1  0  0  0  0
 73 75  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178103484

> <PUBCHEM_SUBSTANCE_VERSION>
5

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
6902

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: TRV027 (TRV120027) is a synthetic analogue of endogenous angiotensin II peptide [PMID:20801892]. It acts as a beta-arrestin biased ligand of the angiotensin II type 1 receptor (AT1R). TRV027 inhibits angiotensin II-mediated vasoconstriction, increases cardiomyocyte contractility and induces an anti-apoptotic effect, all of which when combined, provide a cardioprotective result.
Clinical use: In vivo, the compound's action is cardioprotective [PMID:21835984][PMID:22891045], and was progressed to phase II clinical trial (NCT01966601) in patients suffering from acute decompensated heart failure [PMID:23813302]. First-in-human results from dosing in healthy volunteers were reported in 2012 [PMID:23813302].  In 2017 it was reported that TRV027 therapy in patients with acute heart failure (AHF) did not improve clinical status through 30-day follow-up compared with placebo [PMID:28459958].     COVID-19: As the SARS-CoV-2 virus binds to ACE2 in the lungs, and effectively downregulates its normal function, levels of angiotensin II (ATII) increase. This drives overactivation of the AT1 receptor, and this likely contributes towards downstream acute lung injury. As a functional AT1 receptor antagonist, TRV027 has potential to reverse the effects of elevated ATII.   A clinical trial of TRV027 (NCT04419610; Imperial College London) will be carried out to establish if antagonising the renin-angiotensin system has efficacy to combat acute lung injury and ARDS in COVID-19 patients. If successful this would offer an additional option to anti-virals and anti-inflammatory therapies to address the umet clinical need for treatments for this multi-system, multi-organ disease.

> <PUBCHEM_SUBSTANCE_SYNONYM>
TRV027
TRV 120027
TRV-027
TRV-120027
TRV120027
GTPL6902

> <PUBCHEM_XREF_EXT_ID>
6902

> <PUBCHEM_PUBMED_ID>
20801892
21835984
22891045
23813302
28459958

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6902

> <PUBCHEM_CID_ASSOCIATIONS>
3082475  1

$$$$
178103968
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
178103968

> <PUBCHEM_SUBSTANCE_VERSION>
12

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
7396

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Siltuximab is a monoclonal antibody targeting interleukin 6 (IL-6) [PMID:20625121].Peptide sequences for the heavy and light chains of this antibody are annotated in its IMGT/mAb-DB record. The invention of siltuximab is covered by patent US7291721 .
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: Approved to treat multicentric Castleman's disease (MCD, a.k.a. giant lymph node hyperplasia), a rare blood disorder.SARS-CoV-2 and COVID-19: Siltuximab is being investigated as a mechanism to combat cytokine storm resulting from an exaggerated response of the immune system in patients with severe COVID-19.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Siltuximab is a drug for an orphan (rare) disease.

> <PUBCHEM_SUBSTANCE_SYNONYM>
siltuximab
cLLB8
CNTO 328
Sylvant
GTPL7396

> <PUBCHEM_XREF_EXT_ID>
7396

> <PUBCHEM_PUBMED_ID>
2788466
20625121
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7396

$$$$
178101701
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
178101701

> <PUBCHEM_SUBSTANCE_VERSION>
17

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
5004

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Infliximab is an anti-tumour necrosis factor (TNF)alpha, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFalpha but not lymphotoxin alpha (TNFbeta).Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB  record.Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 .Biosimilars:   NameTrade nameCompanyClinical PhaseIndicationsReferences  infliximab-dyyb; CT-P13Remsima;  Inflectra; FlammegisCelltrion/PfizerApproved (2013 EMA, 2016 FDA)As per reference agent[PMID:27130908][PMID:27650650][PMID:21193033]  infliximab-abda; SB2Flixabi; RenflexisMerck/SamsungBioepisApproved (2016 EMA, 2017 FDA)As per reference agentnbsp  infliximab-qbtx; PF-06438179Ixifi; ZesslyPfizer?SandozApproved (2017 FDA, 2018 EMA)As per reference agent[PMID:27585978]  NI-071nbspNichi-Iko PharmaceuticalApproved (2017 Japan); Phase 3 US (NCT02990806)As per reference agentnbsp  BCD-055nbspBiocadPh 3 (NCT02762838)Rheumatoid arthritisnbsp  Infliximab-EPIRUS; BOW015InfimabEpirus BiopharmaceuticalsApproved (2014 India); Ph 3 US (NCT02683564)Rheumatoid arthritisnbsp     infliximab-axxq; ABP710AvsolaAmgenApproved (2019 FDA)As per reference agentnbsp  STI-002nbspMabTech/Sorrento Therapeuticnbspnbspnbsp  Infliximab biosimilar 1nbspNippon KayakuApproved (Japan 2014)As per reference agent Two more biosimilars have been approved in Japan: Infliximab biosimilar 2 (Nichi-Iko Pharmaceutical/ Yakuhan Pharmaceutical; 2017) and Infliximab biosimilar 3 (Pfizer Japan; 2018), both indicatated as per reference agent .
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: Used in the management of rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease [PMID:7797011] and ulcerative colitis.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Because infliximab was prepared from a murine hybridoma it suffers from the problem of allogenic antigenicity in humans, resulting in fhe generation of anti-infliximab antibodies which neutralizes its therapeutic efficacy. This problem has largely been overcome by the development of engineered antibodies such as 'chimeric', 'humanized' and 'fully human' antibody constructs which are minimally immunogenic.

> <PUBCHEM_SUBSTANCE_SYNONYM>
infliximab
cA2
Inflectra
Remicade
Remsima
SB2
TA-650
GTPL5004

> <PUBCHEM_XREF_EXT_ID>
5004

> <PUBCHEM_PUBMED_ID>
7797011
27130908
21193033
10500056
27650650
27585978
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5004

$$$$
178103237
  -OEChem-02172115172D

 27 31  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  2  0  0  0  0
  4  5  1  0  0  0  0
  5  6  2  0  0  0  0
  6  7  1  0  0  0  0
  2  7  2  0  0  0  0
  5  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  1  0  0  0  0
 12 13  1  0  0  0  0
  8 13  1  0  0  0  0
 12 14  1  0  0  0  0
 14 15  1  0  0  0  0
 15 16  1  0  0  0  0
  8 16  1  0  0  0  0
 15 17  1  0  0  0  0
 10 17  1  0  0  0  0
 15 18  1  0  0  0  0
 18 19  2  0  0  0  0
 18 20  1  0  0  0  0
 20 21  1  0  0  0  0
 21 22  1  0  0  0  0
 22 23  1  0  0  0  0
 23 24  2  0  0  0  0
 24 25  1  0  0  0  0
 25 26  2  0  0  0  0
 26 27  1  0  0  0  0
 22 27  2  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178103237

> <PUBCHEM_SUBSTANCE_VERSION>
5

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
6624

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Opaganib (ABC294640) is an orally bioavailable sphingosine kinase 2-selective inhibitor that is being investigated for clinical antiproliferative efficacy in various cancers [PMID:30060814]. The sphingosine kinases (SK1 and SK2) are key enzymes within the sphingolipid metabolism pathway that promote tumour growth and pathologic inflammation.  Opaganib is being developed by RedHill Bio. In 2017 the FDA granted this compound orphan designation for the treatment of cholangiocarcinoma. SARS-CoV-2 and COVID-19: A medRxiv preprint descibes the compassionate use of opaganib in a small cohort of patients with severe COVID-19 , predicated upon the drug's anti-inflammatory and anti-viral properties. The analysis indicated trends in favour of clinical efficacy which led to extended investigation in a Phase 2 randomised placebo-controlled trial.
Clinical use: ABC294640 has advanced to clinical evaluation in patients with advanced cholangiocarcinoma, advanced hepatocellular carcinoma and refractory/relapsed multiple myeloma (to view ClinicalTrials.gov's list of ABC294640 trials click here).

> <PUBCHEM_SUBSTANCE_SYNONYM>
opaganib
3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide
ABC 294640
ABC-294640
Yeliva
GTPL6624

> <PUBCHEM_XREF_EXT_ID>
6624

> <PUBCHEM_PUBMED_ID>
20061445
30060814

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624

> <PUBCHEM_CID_ASSOCIATIONS>
15604015  1

$$$$
178101665
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
178101665

> <PUBCHEM_SUBSTANCE_VERSION>
7

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
4967

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: IFN-beta is a type I IFN. The peptide sequence of the clinically used recombinant protein IFN-beta-1a is identical to that of the endogenous peptide.
Clinical use: Recombinant  IFN-betas such as IFN-beta1b (recombinant human) and interferon-beta1a are approved to treat multiple sclerosis (MS).SARS-CoV-2 and COVID-19: a formuation of IFN-beta that can be delivered directly to the lungs via a nebuliser (called SNG001) is being developed by Synairgen Research. SNG001 was initially designed to treat viral infection-related exacerbations in COPD patients (currently in Phase 2), but has been rapidly re-deployed for coronavirus infection. Preliminary data from Phase 2 study NCT04385095 are extremely encouraging- this news article by the European Pharmaceutical Review provides more details.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: IFN-beta is produced in large quantities by fibroblasts. It binds the IFN-alpha/beta receptor (IFNAR), a dimeric receptor that consists of protein chains encoded by the IFNAR1 and IFNAR2 genes, and induces expression of proteins containing ISRE or GAS transcription elements. It is a potent modulator of the immune response to viral infection.

> <PUBCHEM_SUBSTANCE_SYNONYM>
IFN-beta
interferon beta
Avonex (recombinant IFN-beta-1a)
fibroblast interferon
GTPL4967

> <PUBCHEM_XREF_EXT_ID>
4967

> <PUBCHEM_NCBI_TAXONOMY_ID>
9606

> <PUBCHEM_PUBMED_ID>
29311663
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4967

$$$$
310264693
  -OEChem-02172115172D

 36 40  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  3  0  0  0  0
  3  4  1  0  0  0  0
  4  5  2  0  0  0  0
  4  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
  6 10  1  0  0  0  0
 10 12  1  0  0  0  0
 12 13  2  0  0  0  0
 13 14  1  0  0  0  0
 14 15  2  0  0  0  0
 15 16  1  0  0  0  0
 12 16  1  0  0  0  0
 16 17  1  0  0  0  0
 17 18  2  0  0  0  0
 18 19  1  0  0  0  0
 19 20  2  0  0  0  0
 15 20  1  0  0  0  0
 20 21  1  0  0  0  0
 14 22  1  0  0  0  0
 22 23  1  0  0  0  0
 23 24  2  0  0  0  0
 24 25  1  0  0  0  0
 25 26  2  0  0  0  0
 26 27  1  0  0  0  0
 22 27  2  0  0  0  0
 25 28  1  0  0  0  0
 28 29  2  0  0  0  0
 28 30  1  0  0  0  0
 30 31  1  0  0  0  0
 31 32  1  0  0  0  0
 32 33  2  0  0  0  0
 33 34  1  0  0  0  0
 34 35  2  0  0  0  0
 35 36  1  0  0  0  0
 31 36  2  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
310264693

> <PUBCHEM_SUBSTANCE_VERSION>
8

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
8912

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Acalabrutinib is an orally available second-generation, selective and irreversible inhibitor of Bruton tyrosine kinase (BTK) [PMID:26957112], being investigated for its potential antineoplastic activity (in multiple haematologic malignancies and solid tumours), as well as a potential therapy for rheumatoid arthritis. Acalabrutinib covalently bonds to Cysteine-481 in BTK.
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Having already received FDA Orphan Drug Designation and Breakthrough Therapy Designation for mantle cell lymphoma (MCL: a rare and fast-growing type of non-Hodgkin lymphoma), in August 2017 the FDA granted priority review for acalabrutinib's New Drug Application (NDA), based on results from a Phase 2 study in relapsed/refractory MCL (NCT02213926). This resulted in full FDA approval in October 2017 (link to FDA announcement). This approval is for the treatment of MCL patients who have received at least one prior therapy.  For a list of all registered acalabrutinib trials, link here to ClinicalTrials.gov. In November 2019, FDA approval was expanded to include treatment of CLL or SLL, following evaluation in trials including NCT02475681 and NCT02970318; clinial trial results in patients with CLL are reported in [PMID:31724010], [PMID:26641137] and [PMID:31088809].Trials to assess acalabrutinib's efficacy in a variety of solid tumours (such as bladder, prostate and non-small cell lung cancers) are ongoing. In the European Union, the EMA has granted acalabrutinib orphan designation for three rare diseases (as of 2016): CLL/SLL, lymphoplasmacytic lymphoma and MCL. In response to the SARS-CoV-2 pandemic plans are underway to evaluate acalabrutinib in COVID-19 patients, as part of the UK's Accelerating COVID-19 Research and Development (ACCORD) initiative (June 2020).  ACCORD aims to fast-track potential treatments for COVID-19 through early-stage clinical trials . In this setting researchers would aim to determine if the anti-inflammatory action of BTK-inhibition has efficacy to reduce mortality in patients with severe COVID-19.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Pharmacological inhibition of BTK prevents the activation of B cells and BTK-mediated activation of downstream survival pathways. This leads to inhibition of the growth of malignant B cells overexpressing BTK.

> <PUBCHEM_SUBSTANCE_SYNONYM>
acalabrutinib
4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
ACP-196
Calquence
Example 6 [US20140155385 A1]
GTPL8912

> <PUBCHEM_XREF_EXT_ID>
8912

> <PUBCHEM_PUBMED_ID>
31088809
31724010
26641137
26957112
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8912

> <PUBCHEM_CID_ASSOCIATIONS>
71226662  1

$$$$
178100871
  -OEChem-02172115172D

 45 49  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  2  0  0  0  0
  4  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  7  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  1  0  0  0  0
 11 13  1  0  0  0  0
 13 14  1  0  0  0  0
 13 15  1  0  0  0  0
  7 15  1  0  0  0  0
 13 16  1  0  0  0  0
 16 17  1  0  0  0  0
 17 18  1  0  0  0  0
 17 19  1  0  0  0  0
 19 20  1  0  0  0  0
 19 21  1  0  0  0  0
 21 22  1  0  0  0  0
 11 21  1  0  0  0  0
 21 23  1  0  0  0  0
 23 24  2  0  0  0  0
 24 25  1  0  0  0  0
 25 26  1  0  0  0  0
 26 27  2  0  0  0  0
 27 28  1  0  0  0  0
 28 29  2  0  0  0  0
 29 30  1  0  0  0  0
 25 30  2  0  0  0  0
 28 31  1  0  0  0  0
 31 32  1  0  0  0  0
 32 33  2  0  0  0  0
 33 34  1  0  0  0  0
 34 35  2  0  0  0  0
 35 36  1  0  0  0  0
 31 36  2  0  0  0  0
 35 37  1  0  0  0  0
 19 38  1  0  0  0  0
 38 39  1  0  0  0  0
 38 40  1  0  0  0  0
 40 41  1  0  0  0  0
 17 41  1  0  0  0  0
 41 42  2  0  0  0  0
 38 43  1  0  0  0  0
 23 44  1  0  0  0  0
 24 45  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178100871

> <PUBCHEM_SUBSTANCE_VERSION>
9

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
4047

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Vorapaxar is an orally active thrombin receptor (PAR1) antagonist based on the natural product himbacine [PMID:18447380], that is used as an anti-thrombosis drug.
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Approved to reduce the risk of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). SARS-CoV-2 and COVID-19: Antagonism of PAR1 and the resulting anti-thrombotic action may be applicable to the management of pathological thrombosis and endotheliitis in patients with severe COVID-19 [PMID:32639031].

> <PUBCHEM_SUBSTANCE_SYNONYM>
vorapaxar
ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-naphtho[6,7-c]furan-7-yl]carbamate
SCH 530348
SCH-530348
SCH530348
Zontivity
GTPL4047

> <PUBCHEM_XREF_EXT_ID>
4047

> <PUBCHEM_PUBMED_ID>
18447380
20670195
32639031

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4047

> <PUBCHEM_CID_ASSOCIATIONS>
10077130  1

$$$$
178101031
  -OEChem-02172115172D

 84 87  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  2  0  0  0  0
  2  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  5  7  1  0  0  0  0
  7  8  1  0  0  0  0
  7  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
 10 12  1  0  0  0  0
 12 13  1  0  0  0  0
 12 14  1  0  0  0  0
 14 15  1  0  0  0  0
 15 16  1  0  0  0  0
 15 17  1  0  0  0  0
 17 18  1  0  0  0  0
 17 19  1  0  0  0  0
 19 20  1  0  0  0  0
 10 19  1  0  0  0  0
 19 21  1  0  0  0  0
 17 22  1  0  0  0  0
 15 23  1  0  0  0  0
 23 24  1  0  0  0  0
 24 25  1  0  0  0  0
 24 26  1  0  0  0  0
 26 27  1  0  0  0  0
 26 28  1  0  0  0  0
 26 29  1  0  0  0  0
 29 30  1  0  0  0  0
 30 31  1  0  0  0  0
 30 32  1  0  0  0  0
 32 33  1  0  0  0  0
 32 34  1  0  0  0  0
 34 35  1  0  0  0  0
 24 34  1  0  0  0  0
 34 36  1  0  0  0  0
 36 37  1  0  0  0  0
 37 38  2  0  0  0  0
 37 39  2  0  0  0  0
 37 40  1  0  0  0  0
 32 41  1  0  0  0  0
 41 42  1  0  0  0  0
 42 43  2  0  0  0  0
 42 44  2  0  0  0  0
 42 45  1  0  0  0  0
 30 46  1  0  0  0  0
 46 47  1  0  0  0  0
 47 48  1  0  0  0  0
 47 49  1  0  0  0  0
 49 50  1  0  0  0  0
 49 51  1  0  0  0  0
 51 52  1  0  0  0  0
 52 53  1  0  0  0  0
 53 54  1  0  0  0  0
 53 55  1  0  0  0  0
 55 56  1  0  0  0  0
 47 55  1  0  0  0  0
 55 57  1  0  0  0  0
 53 58  1  0  0  0  0
 58 59  1  0  0  0  0
 59 60  2  0  0  0  0
 59 61  2  0  0  0  0
 59 62  1  0  0  0  0
 52 63  1  0  0  0  0
 49 64  1  0  0  0  0
 64 65  2  0  0  0  0
 64 66  1  0  0  0  0
 12 67  1  0  0  0  0
 67 68  2  0  0  0  0
 67 69  1  0  0  0  0
  7 70  1  0  0  0  0
 70 71  1  0  0  0  0
 71 72  1  0  0  0  0
 71 73  1  0  0  0  0
 73 74  1  0  0  0  0
 73 75  1  0  0  0  0
 75 76  1  0  0  0  0
  5 75  1  0  0  0  0
 75 77  1  0  0  0  0
 73 78  1  0  0  0  0
 71 79  1  0  0  0  0
 79 80  1  0  0  0  0
 80 81  1  0  0  0  0
 81 82  2  0  0  0  0
 81 83  2  0  0  0  0
 81 84  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178101031

> <PUBCHEM_SUBSTANCE_VERSION>
10

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
4214

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: The exact structure of commercial heparin varies according to the conformation of its disaccharide subunits. Heparin is a polymer made up from carbohydrate subunits. The structure shown here matches the structure for the CAS registry number 9005-49-6. A natural product, found in various species, heparin is used clinically as an anti-coagulant. Commercial preparations usually vary in size from 12-15 kDa, while a low molecular weight variant is also available. Database entries may specify the sodium salt forms.
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_who - Substance is included in WHO Essential Medicines List.
Clinical use: Heparin is used clinically as an anti-coagulant. In response to the SARS-CoV-2 pandemic plans are underway to evaluate haparin in COVID-19 patients, as part of the UK's Accelerating COVID-19 Research and Development (ACCORD) initiative (June 2020).  ACCORD aims to fast-track potential treatments for COVID-19 through early-stage clinical trials . In this setting heparin will primarily be acting classically as an anti-coagulant to reduce mortality caused by COVID-associated thromboembolic events [PMID:32220112][PMID:32399449]. It may also have non-anticoagulant activities that are beneficial in this disease [PMID:32426897].

> <PUBCHEM_SUBSTANCE_SYNONYM>
heparin
heparin sodium
(2S,3S,4R,5R,6R)-6-{[(2S,3S,4S,5R,6S)-6-{[(2R,3S,4S,5R)-2-carboxy-4,6-dihydroxy-5-(sulfooxy)oxan-3-yl]oxy}-2-hydroxy-4-(sulfomethyl)-5-(sulfooxy)oxan-3-yl]oxy}-3-{[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-[(sulfooxy)methyl]oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid
HepFlush
GTPL4214

> <PUBCHEM_XREF_EXT_ID>
4214

> <PUBCHEM_PUBMED_ID>
32220112
23598032
32426897
32399449
32653452

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214

> <PUBCHEM_CID_ASSOCIATIONS>
22833565  1

$$$$
178103463
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
178103463

> <PUBCHEM_SUBSTANCE_VERSION>
14

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
6881

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Tocilizumab is an anti-IL-6 receptor mAb, with immunosuppressive action [PMID:17028666] that is approved for chronic autoimmune indications.Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.Qyuns Therapeutics have a potential tocilizumab biosimilar (QX003S) in Phase 1 evaluation for rheumatoid arthritis (trial registry number ChiCTR1900021808).SARS-CoV-2 and COVID-19:  In early March 2020, China's National Health Commission issued guidance that allows use of tocilizumab to treat patients with serious COVID-19-induced lung damage. Tocilizumab is predicted to mitigate against the uncontrolled immune response that is triggered by SARS-CoV-2 infection [PMID:32301997][PMID:32601708] in some patients and which leads to potentially life-threatening damage to the lungs and other organs. Clinical trials are beginning to reveal outcomes (Oct 2020), but the level of benefit remains unclear [PMID:33080002][PMID:33085857][PMID:33080017][PMID:33080005] and requires further investigations. Differences between the studies (timing of treatment, severity of disease at initiation of treatment etc.) make it difficult to compare results and form a solid conclusion.
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: Tocilizumab had been approved in Japan in 2005 as a treament for giant lymph node hyperplasia (Castleman's disease) [PMID:17541233], before being granted EMA and FDA approvals for use as a treatment for rheumatoid arthritis [PMID:16947782][PMID:18407769] and systemic and polyarticular juvenile idiopathic arthritis [PMID:16129907].In May 2017 tocilizumab became the first FDA approved drug for the treatment of adults with giant cell arteritis.Phase 3 clinical trials for immune conditions including ankylosing spondylitis, hand osteoarthritis, systemic sclerosis and primary Sjoumlgren's syndrome (pSS) are ongoing. Tocilizumab was initally used off-label to manage severe or life-threatening cytokine release syndrome (CRS), which is a serious, and potentially life-threatening side effect of CAR T-cell therapy. In September 2017, the FDA extended tocilizumab approval to include treatment of CAR T-cell therapy-induced CRS. It was approved particularly to manage CRS in patients ge2 years of age receiving tisagenlecleucel (Kymriah,CTL019), the first CAR T-cell therapy approved for relapsed and refractory B-cell ALL.   SARS-CoV-2 and COVID-19: China's National Health Commission authorised tocilizumab as a treatment for serious COVID-19 lung damage early on in the outbreak. The Chinese Clinical Trial Registry has two studies that are designed to evaluate tocilizumab efficacy in patients with severe COVID-19 pneumonia (Registration Numbers ChiCTR2000029765 and ChiCTR2000030442).  Results from an observational study, of low-dose tocilizumab in patients with confirmed elevations in inflammatory markers, showed an indication of reduced mortality . This finding was not confirmed by preliminary results from Roche's Phase 3 COVACTA RCT (NCT04320615). The limitations and differences between the studies, and reasoning that might explain the apparently contradictory findings are discussed by Campochiaro and Dagna (2020) .     In addition, early results from 20 severe COVID-19 patients treated with tocilizumab have been posted on the preprint server of the Chinese Academy of Sciences (ChinaRix) (url http://www.chinaxiv.org/abs/202003.00026, DOI: 10.12074/202003.00026). Tocilizumab appears to have reduced disease symptoms and aided full recovery in 19/20 patients. In mid-March 2020, the National Cancer Institute in Naples (Italy) began a Phase 2 observational trial of tocilizumab in patients with COVID-19 pneumonia; this study is named TOCIVID-19, and has clinicaltrials.gov registry ID NCT04317092.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Tocilizumab blocks IL-6R activation, which in turn leads to a reduction in cytokine and acute phase reactant production, and eventual symptomatic relief.

> <PUBCHEM_SUBSTANCE_SYNONYM>
tocilizumab
Actemra
R-1569
RG-1569
RHPM-1
RoActemra
GTPL6881

> <PUBCHEM_XREF_EXT_ID>
6881

> <PUBCHEM_PUBMED_ID>
16129907
17028666
16947782
16102523
17541233
18407769
18071945
30199509
33080002
33085857
33080005
33080017
32301997
32601708
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881

$$$$
178102315
  -OEChem-02172115172D

 25 28  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  3  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  4  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  2  0  0  0  0
  8  9  1  0  0  0  0
  9 10  2  0  0  0  0
  6 10  1  0  0  0  0
  9 11  1  0  0  0  0
 11 12  1  0  0  0  0
 12 13  2  0  0  0  0
 13 14  1  0  0  0  0
 14 15  2  0  0  0  0
 15 16  1  0  0  0  0
 11 16  2  0  0  0  0
 16 17  1  0  0  0  0
 17 18  2  0  0  0  0
 18 19  1  0  0  0  0
 19 20  1  0  0  0  0
 15 19  1  0  0  0  0
  4 21  1  0  0  0  0
 21 22  1  0  0  0  0
 22 23  1  0  0  0  0
 23 24  1  0  0  0  0
 24 25  1  0  0  0  0
 21 25  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178102315

> <PUBCHEM_SUBSTANCE_VERSION>
15

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
5688

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Ruxolitinib is a Type-1 kinase inhibitor and was first approved by the US FDA in 2011. Ruxolitinib has high potency against Janus kinases 1 and 2 (JAK1, JAK2), as well as against the related family member, tyrosine kinase 2 (TYK2) [PMID:23061660]. Inhibitory activity against JAK3 is only slightly reduced compared to the other three family kinases.Marketed formulations may contain ruxolitinib phosphate (PubChem CID 25127112).
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Used to treat intermediate or high-risk myelofibrosis including including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis.In 2014 ruxolitinib was approved for use as a treatment for polycythemia vera, a chronic type of bone marrow disease.In May 2019, the FDA approved ruxolitinib as a treatment for steroid-refractory acute graft-versus-host disease (GvHD) in patients ge12 years old.Interesting results from small trials in patients with alopecia areata suggest that by killing the immune cells responsible for hair loss in this disease, ruxolitinib can promote hair re-growth [PMID:25129481][PMID:27699253].
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).

> <PUBCHEM_SUBSTANCE_SYNONYM>
ruxolitinib
(3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanenitrile
(R)-ruxolitinib
INC424
INCB 18424
INCB018424
Jakafi
Jakavi
GTPL5688

> <PUBCHEM_XREF_EXT_ID>
5688

> <PUBCHEM_PUBMED_ID>
25129481
22037378
21095574
24417533
20130243
27699253
23061660
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688

> <PUBCHEM_CID_ASSOCIATIONS>
25126798  1

$$$$
315661179
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
315661179

> <PUBCHEM_SUBSTANCE_VERSION>
10

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
9094

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Lanadelumab is a fully human monoclonal antibody targeting the serine peptidase kallikrein B1 (KLKB1, a.k.a. plasma kallikrein). It is generated in recombinant Chinese hamster ovary cells.Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent US8816055 .
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: Lanadelumab was evaluated in Phase 3 clinical trial in patients with hereditary angioedema (HAE)- see NCT02586805. The EMA granted orphan drug designation in 2015, and the FDA (2017) has designated lanadelumab as a breakthrough therapy for prevention of HAE attacks. In 2018, the EMA and FDA granted lanadelumab (Takhzyro) full approval as a prophylactic for the prevention of swelling attacks caused by types I and II HAE. It can be prescribed for patients 12 years and older.COVID-19: Elevated levels of bradykinin have been detected in COVID-19 patients, and it is proposed that this might underlie many of the highly debilitating symptoms of the infection [PMID:32633718][PMID:32359101]. By inhibiting the plasma kallikrein-bradykinin axis lanadelumab provides an existing therapeutic option with potential to reduce the multi-system effects of bradykinin. SARS-CoV-2 destruction of ACE2 could participate in the loss of regulation of bradykinin levels [PMID:32818486]. icatibant also acts on this pathway (it antagonises bradykinin signalling via its receptor), and is being tested in COVID-19 patients.

> <PUBCHEM_SUBSTANCE_SYNONYM>
lanadelumab
DX-2930
lanadelumab-flyo
Takhzyro
X124-G01
GTPL9094

> <PUBCHEM_XREF_EXT_ID>
9094

> <PUBCHEM_PUBMED_ID>
32633718
32359101
32818486

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9094

$$$$
318164814
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
318164814

> <PUBCHEM_SUBSTANCE_VERSION>
9

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
9295

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Emapalumab (NI-0501) is a fully human monoclonal antibody that targets interferon gamma (IFNgamma).Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2006109191, and in which NI-0501 is confirmed as an exemplary antibody .
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: Emapalumab initially received FDA orphan drug designation for the treatment of hemophagocytic lymphohistiocytosis (HLH). Link here to the FDA record for this designation.Phase 2/3 clinical trial NCT01818492 evaluated emapalumab (NI-0501) in children with primary HLH, and a long-term follow-up study of HLH patients who were given emapalumab in an earlier clinical trial is ongoing (see NCT02069899). In November 2018, the FDA granted full approval for emapalumab's use as a treament option for adult and pediatric (newborn and older) patients with refractory, recurrent or progressive primary HLH or who are intolerant to conventional HLH therapy.SARS-CoV-2 and COVID-19: Emapalumab has been entered in to clinical trials that aim to determine its ability to combat the exaggerated immune response that drives cytokine storm and leads to tissue damage in the lung and other organs in patients with severe COVID-19.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Emapalumab is an anti-IFNgamma therapy. It is the first drug specifically targeted for the treatment of primary HLH, and represents a major advance in treatment for this ultra-rare syndrome.

> <PUBCHEM_SUBSTANCE_SYNONYM>
emapalumab
emapalumab-lzsg
Gamifant
NI-0501
NI0501
GTPL9295

> <PUBCHEM_XREF_EXT_ID>
9295

> <PUBCHEM_PUBMED_ID>
20049711
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9295

$$$$
405067326
  -OEChem-02172115172D

 41 44  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  1  0  0  0  0
  4  9  1  0  0  0  0
  7 10  1  0  0  0  0
 10 11  2  0  0  0  0
 10 12  1  0  0  0  0
 12 13  1  0  0  0  0
 12 14  1  0  0  0  0
 14 15  1  0  0  0  0
 15 16  2  0  0  0  0
 15 17  2  0  0  0  0
 15 18  1  0  0  0  0
 18 19  1  0  0  0  0
 19 20  2  0  0  0  0
 20 21  1  0  0  0  0
 21 22  2  0  0  0  0
 22 23  1  0  0  0  0
 18 23  2  0  0  0  0
 22 24  1  0  0  0  0
 24 25  2  0  0  0  0
 25 26  1  0  0  0  0
 26 27  1  0  0  0  0
 27 28  1  0  0  0  0
 28 29  2  0  0  0  0
 24 29  1  0  0  0  0
 29 30  1  0  0  0  0
 27 31  1  0  0  0  0
 12 32  1  0  0  0  0
 32 33  1  0  0  0  0
 33 34  1  0  0  0  0
 34 35  2  0  0  0  0
 35 36  1  0  0  0  0
 36 37  2  0  0  0  0
 37 38  1  0  0  0  0
 33 38  2  0  0  0  0
 37 39  1  0  0  0  0
 39 40  2  0  0  0  0
 39 41  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
405067326

> <PUBCHEM_SUBSTANCE_VERSION>
1

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10733

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: I-432 is an inhibitor of the serine protease TMPRSS2 [PMID:27277342]. TMPRSS2, present in human airway cells, is involved in processes that support infection by a number of  viruses [PMID:25203900], thus inhibitors of this protease are being investigated for anti-viral potential.

> <PUBCHEM_SUBSTANCE_SYNONYM>
I-432
3-[(2R)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[3-(4,6-dichlorocyclohexa-1,5-dien-1-yl)benzenesulfonamido]-3-oxopropyl]benzene-1-carboximidamide
I432
GTPL10733

> <PUBCHEM_XREF_EXT_ID>
10733

> <PUBCHEM_PUBMED_ID>
25203900
27277342

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10733

> <PUBCHEM_CID_ASSOCIATIONS>
146025595  1

$$$$
178101079
  -OEChem-02172115172D

 26 28  0     0  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  2  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  2  0  0  0  0
  6  7  1  0  0  0  0
  7  8  2  0  0  0  0
  8  9  1  0  0  0  0
  4  9  2  0  0  0  0
  7 10  1  0  0  0  0
 10 11  2  0  0  0  0
 10 12  1  0  0  0  0
 12 13  1  0  0  0  0
 13 14  1  0  0  0  0
 14 15  2  0  0  0  0
 15 16  1  0  0  0  0
 16 17  2  0  0  0  0
 17 18  1  0  0  0  0
 13 18  2  0  0  0  0
 17 19  1  0  0  0  0
 19 20  2  0  0  0  0
 20 21  1  0  0  0  0
 21 22  2  0  0  0  0
 16 22  1  0  0  0  0
 21 23  1  0  0  0  0
 23 24  2  0  0  0  0
 23 25  1  0  0  0  0
  2 26  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178101079

> <PUBCHEM_SUBSTANCE_VERSION>
13

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
4262

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Nafamostat is a guanidinobenzoate-containing inhibitor, with activity against a range of serine proteases. Some data is attached to nafamostat mesylate (PubChem CID 5311180).
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Used in Japan as an anticoagulant and to treat pancreatic cancer.SARS-CoV-2 and COVID-19: In Japan, a combination therapy of nafamostat plus favipiravir is being evaluated in patients with COVID-19 pneumonia (clinical trial jRCTs031200026) . Favipiravir is being included for its antiviral action, and nafamostat is being proposed to reduce SARS-CoV-2 entry by inhiiting the host protease TMPRSS2 [PMID:27550352][PMID:32312781], and to additionally counteract COVID-19-associated thrombosis via its anticoagulant activity.

> <PUBCHEM_SUBSTANCE_SYNONYM>
nafamostat
6-carbamimidoylnaphthalen-2-yl 4-[(diaminomethylidene)amino]benzoate
FUT-175
GTPL4262

> <PUBCHEM_XREF_EXT_ID>
4262

> <PUBCHEM_PUBMED_ID>
12939527
21122141
17826743
9544206
27550352
32312781

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262

> <PUBCHEM_CID_ASSOCIATIONS>
4413  1

$$$$
178103899
  -OEChem-02172115172D

 19 21  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  2  0  0  0  0
  3  4  1  0  0  0  0
  4  5  2  0  0  0  0
  4  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  2  8  1  0  0  0  0
  6  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  2  0  0  0  0
 10 12  1  0  0  0  0
 12 13  1  0  0  0  0
 13 14  1  0  0  0  0
  9 14  1  0  0  0  0
 14 15  2  0  0  0  0
 13 16  2  0  0  0  0
 16 17  1  0  0  0  0
 17 18  2  0  0  0  0
 18 19  1  0  0  0  0
 12 19  2  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178103899

> <PUBCHEM_SUBSTANCE_VERSION>
9

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
7327

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Thalidomide is principally an immunomodulatory drug. It inhibits synthesis of TNFalpha. Mechanistically, thalidomide binds to cereblon, and this complex recruits substrate proteins for degradation by the ubiquitin system. The lymphoid transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) have been identified as substrates for thalidomide-bound cereblon. More recently another transcription factor, PLZF (ZBTB16), has been reported as a potential thalidomide/cereblon substrate . Knockdown of Plfz induces skeletal abnormalities in chicken limbs, so thalidomide-targeted degradation of PLZF would be predicted to exhibit similar teratogenic effects.    SARS-CoV-2 and COVID-19: Thalidomide + low-dose glucocorticoid is being evaluated for efficacy in severe COVID-19 pneumonia (preprint available here https://www.preprints.org/manuscript/202002.0395/v1). An alternative approach is examining the combination of thalidomide + celecoxib (which targets NF-kappaB to suppress production of inflammatory cytokines; see preprint DOI: 10.13140/RG.2.2.26979.91689).
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_who - Substance is included in WHO Essential Medicines List.
Clinical use: Thalidomide was originally used treat nausea and alleviate morning sickness in pregnant women. Unfortunately the drug was found to be a powerful human teratogen, causing severe embryopathy, principally malformation of the limbs (phocomelia). This drug has undergone a remarkable metamorphosis, with thalidomide now being repurposed as a treatment for certain cancers (eg multiple myeloma, in combination with dexamethasone, or melphalan and prednisone) and for erythema nodosum leprosum (ENL), a complication of leprosy. As a condition of drug approval, authorising agencies stipulate that female patients with childbearing potential, requiring thalidomide treatment, be advised to use multiple forms of contraception and/or be counselled and educated regarding the risks associated with taking the drug, and the importance of avoiding pregnancy. They may also be offered regular pregnancy tests.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Included in GtoImmuPdb for its ability to inhibit TNFalpha synthesis.

> <PUBCHEM_SUBSTANCE_SYNONYM>
thalidomide
2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione
K-17
GTPL7327

> <PUBCHEM_XREF_EXT_ID>
7327

> <PUBCHEM_PUBMED_ID>
20223979
22552008
16045448
17380424
22770990
27294876
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7327

> <PUBCHEM_CID_ASSOCIATIONS>
5426  1

$$$$
223366123
  -OEChem-02172115172D

 27 30  0     0  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  3  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  4  7  1  0  0  0  0
  6  8  1  0  0  0  0
  8  9  2  0  0  0  0
  8 10  2  0  0  0  0
  8 11  1  0  0  0  0
 11 12  1  0  0  0  0
  4 13  1  0  0  0  0
 13 14  1  0  0  0  0
 14 15  2  0  0  0  0
 15 16  1  0  0  0  0
 16 17  2  0  0  0  0
 13 17  1  0  0  0  0
 16 18  1  0  0  0  0
 18 19  1  0  0  0  0
 19 20  2  0  0  0  0
 20 21  1  0  0  0  0
 21 22  2  0  0  0  0
 22 23  1  0  0  0  0
 18 23  2  0  0  0  0
 23 24  1  0  0  0  0
 24 25  2  0  0  0  0
 25 26  1  0  0  0  0
 26 27  1  0  0  0  0
 22 26  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
223366123

> <PUBCHEM_SUBSTANCE_VERSION>
13

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
7792

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Baricitinib is a JAK1 and 2 selective inhibitor. The compound is orally bioavailable.SARS-CoV-2 and COVID-19: Through the application of proprietary artificial intelligence (AI) algorithms baricitinib has been predicted to possess antiviral activity in addition to its known anti-inflammatory efficacy [PMID:32113509][PMID:32032529]. Antiviral activity is predicted to arise from inhibition of the numb-associated kinase (NAK) AAK1 which is an important regulator of clathrin-mediated endocytosis. Inhibition of AAK1 would likely reduce the ability of viruses to infect lung cells, and is being proposed as a pharmacological mechanism that warrants further investigation as a treatment for SARS-CoV-2 infection (COVID-19 disease). In addition, the powerful anti-inflammatory activity of baricitinib (and potentially other approved JAK inhibitors such as fedratinib, and ruxolitinib) is likely to be effective against the pathological effects of raised cytokine levels (e.g. interferon gamma) in patients with severe COVID-19. Short term use of baricitinib during the course of SARS-CoV-2 infection (7-14 days) is not anticipated to cause serious side-effects.
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: The EMA granted baricitinib marketing authorisation in February 2017, for the treatment of rheumatoid arthritis (RA). This approval covered doses of either 2 or 4 mg. Phase 3 trial results reporting significant clinical improvement in patients who's symptoms had failed to respond to other disease-modifying antirheumatic drugs (DMARDs) were published in [PMID:27028914]. These are the results of the RA-BEACON study NCT01721044. FDA approval, as a once daily treatment for moderately-to-severely active RA, in patients with an inadequate response to one or more tumour necrosis factor (TNF) inhibitor therapies, was granted in June 2018, but only for the 2 mg dose. In both jurisdictions, baricitinib can be used as monotherapy, or in combination with methotrexate or other non-biologic DMARDs. Use of baricitinib in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporin A is not recommended.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Baricitinib-induced inhibition of JAKs 1 and 2,  down-modulates the intracellular signalling that is induced by multiple proinflammatory cytokines, including IL-6 and IL-23 that are elevated in patients with autoimmune diseases. This action evokes an improvement in clinical measures of autoinflammatory diseases.Unfortunately, baricitinib causes adverse events (thrombosis and elevated platelet counts) that don't appear to be common to other JAK inhibitors that are in development, for example the JAK1-selective inhibitors upadacitinib and filgotinib, which suggests that inhibition of JAK2 may be the culprit. Note that as immunosuppressants, all currently marketed JAK inhibitor class drugs (ruxolitinib and tofacitinib for human treatment) pose the risk of serious side-effects, such as increased risk of serious infection or malignancy. This risk is exemplified by the boxed warning on the package insert for Pfizer's JAK3-selective inhibitor tofacitinib (Xeljanz).

> <PUBCHEM_SUBSTANCE_SYNONYM>
baricitinib
2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
INCB-028050
INCB028050
LY-3009104
LY3009104
Olumiant
GTPL7792

> <PUBCHEM_XREF_EXT_ID>
7792

> <PUBCHEM_PUBMED_ID>
25129481
24417533
32113509
20363976
32032529
27699253
27699252
27028914
26137574
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792

> <PUBCHEM_CID_ASSOCIATIONS>
44205240  1

$$$$
340590254
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
340590254

> <PUBCHEM_SUBSTANCE_VERSION>
7

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
9624

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Gimsilumab (MORAb-022) is an investigational, fully human IgG1 monoclonal antibody being evaluated for its potential in the treatment of multiple inflammatory diseases and cancer. It targets granulocyte-macrophage colony stimulating factor (GM-CSF, CSF2), a growth factor involved in autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and asthma. In the cancer setting, MORAb-022-mediated blocking of CSF2 produces a pro-immunity microenvironment that leads to tumour tissue death in preclinical studies. Peptide sequences (from the WHO INN submission for gimsilumab) match sequences 8 and 12 from Morphotek Inc. patent WO2007092939 , and these sequences belong to monoclonal antibody clone G9 specified in the patent.
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: Phase 1 study (NCT01357759) in healthy volunteers and patients with rheumatoid arthritis has been completed. SARS-CoV-2 and COVID-19: In response to the urgent medical need caused by SARS-CoV-2, gimsilumab is being investigated for anti-inflammatory potential in COVID-19 patients. The hypothesis being to reduce the raging cytokine storm that can arise secondary to SARS-CoV-2 infection.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: MORAb-022  targets granulocyte-macrophage colony stimulating factor (GM-CSF, CSF2), a growth factor involved in autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and asthma.

> <PUBCHEM_SUBSTANCE_SYNONYM>
gimsilumab
MORAb-022
GTPL9624

> <PUBCHEM_XREF_EXT_ID>
9624

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9624

$$$$
405067310
  -OEChem-02172115172D

 56 58  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  4  6  1  0  0  0  0
  6  7  2  0  0  0  0
  6  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
  9 11  1  0  0  0  0
 11 12  1  0  0  0  0
 12 13  1  0  0  0  0
 12 14  1  0  0  0  0
 14 15  1  0  0  0  0
 15 16  1  0  0  0  0
 16 17  1  0  0  0  0
 12 17  1  0  0  0  0
 17 18  2  0  0  0  0
  9 19  1  0  0  0  0
 19 20  2  0  0  0  0
 20 21  1  0  0  0  0
 21 22  2  0  0  0  0
 21 23  1  0  0  0  0
 23 24  1  0  0  0  0
 24 25  1  0  0  0  0
 25 26  1  0  0  0  0
 26 27  2  0  0  0  0
 27 28  1  0  0  0  0
 28 29  2  0  0  0  0
 29 30  1  0  0  0  0
 25 30  2  0  0  0  0
  4 31  1  0  0  0  0
 31 32  1  0  0  0  0
 32 33  2  0  0  0  0
 32 34  1  0  0  0  0
 34 35  1  0  0  0  0
 34 36  1  0  0  0  0
 36 37  1  0  0  0  0
 36 38  1  0  0  0  0
 34 39  1  0  0  0  0
 39 40  1  0  0  0  0
 40 41  2  0  0  0  0
 40 42  1  0  0  0  0
 42 43  1  0  0  0  0
 42 44  1  0  0  0  0
 44 45  1  0  0  0  0
 45 46  2  0  0  0  0
 45 47  1  0  0  0  0
 47 48  2  0  0  0  0
 48 49  1  0  0  0  0
 49 50  1  0  0  0  0
 50 51  2  0  0  0  0
 47 51  1  0  0  0  0
 50 52  1  0  0  0  0
 42 53  1  0  0  0  0
  2 54  1  0  0  0  0
 19 55  1  0  0  0  0
 20 56  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
405067310

> <PUBCHEM_SUBSTANCE_VERSION>
1

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10716

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: PRD_002214 is an irreversible peptide-like inhibitor of the main protease (MPRO) of SARS-CoV-2 . The chemical structure was obtained from the RCSB Protein Data Bank entry 6LU7 which shows the ligand in complex with the protease. The article describing the work has not yet been published (March 12, 2020), but the inhibitor (also referred to as N3) has been deployed in other MPRO crystallisation studies [PMID:16128623]. The MPRO sequence is held in the NCBI record 'Chain A, SARS-CoV-2 main protease'.

> <PUBCHEM_SUBSTANCE_SYNONYM>
PRD_002214
benzyl (2Z,4S)-4-[(2S)-4-methyl-2-[(2S)-3-methyl-2-[(2S)-2-[(5-methyl-1,2-oxazol-3-yl)formamido]propanamido]butanamido]pentanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate
inhibitor N3
N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE
GTPL10716

> <PUBCHEM_XREF_EXT_ID>
10716

> <PUBCHEM_PUBMED_ID>
16128623

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10716

> <PUBCHEM_CID_ASSOCIATIONS>
146025593  1

$$$$
354702231
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
354702231

> <PUBCHEM_SUBSTANCE_VERSION>
5

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
9758

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Camrelizumab is a fully human anti-programmed cell death 1 (PD-1) monoclonal antibody being developed as an immuno-oncology therapeutic.SARS-CoV-2 and COVID-19: Clinical efficacy of camrelizumab plus thymosin in patients with COVID-19 will be evaluated in clinical trial NCT04268537.
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: More than 20 clinical trials assessing camrelizumab's anti-tumour activity are registered with ClinicalTrials.gov. The most advanced trials are two Phase 3 clinical trials evaluating camrelizumab's efficacy against lung cancer (NCT03134872) and esophageal carcinoma (NCT03099382). The first global approval of camrelizumab was granted by China in 2019, under which camrelizumab is indicated as a treatment for relapsed/refractory classical Hodgkin lymphoma [PMID:31313098].
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Camrelizumab is another of the growing number of anti-PD-1 monoclonal antibodies being developed as immuno-oncology therapeutics, joining the already clinically approved anti-PD-1 mAbs pembrolizumab and nivolumab.

> <PUBCHEM_SUBSTANCE_SYNONYM>
camrelizumab
INCSHR1210
SHR-1210
GTPL9758

> <PUBCHEM_XREF_EXT_ID>
9758

> <PUBCHEM_PUBMED_ID>
31313098
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9758

$$$$
381118878
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
381118878

> <PUBCHEM_SUBSTANCE_VERSION>
5

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10168

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Ravulizumab (ALXN1210; Ultomiris) is a humanized monoclonal antibody that binds to human complement component C5. It was developed by Alexion as a next-generation anti-C5 therapy for paroxysmal nocturnal hemoglobinuria (PNH) that was engineered from their already approved PNH agent eculizumab (Soliris), but was designed to have an inherently longer circulating half-life so as to extend dosing intervals to once/month [PMID:29649283].Peptide sequence and secondary structural information for this antibody are available from its IMGT/mAb-DB record.
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: Ravulizumab held EMA orphan drug designation to treat PNH patients (granted in 2016) and FDA orphan status for atypical hemolytic uremic syndrome (aHUS; granted in 2017). Therapeutic efficacy in Phase 1b/2 clinical trial was reported in 2018 [PMID:30171081]. FDA full approval for PNH was granted in December 2018, and EMA approval for this indication followed in July 2019. Click here to link to ClinicalTrials.gov's full list of ravulizumab (ALXN1210) trials.  Direct comparison with eculizumab in C5-inhibitor-experienced adult patients with PNH has also been reported and indicates that switching from eculizumab to ravulizumab is safe and that treatment remains effective [PMID:30510079].Motor neuron diseaseDysregulated complement activation is recognised as a key pathogenic driver in a wide range of immune-mediated and inflammatory diseases, including haematological and ocular pathologies, cancer and ageing-related neuroinflammatory and neurodegenerative disorders. Having already committed to testing ravulizumab as a therapy for neuromyelitis optica-driven inflammation and demyelination (in clinical trial NCT04201262), Alexion have declared their intention to evaluate ravulizumab for efficacy in slowing MND-associated neurodegeneration (in a press release Jan 14, 2020 which refers to the Phase 3 CHAMPION-ALS study).SARS-CoV-2 and COVID-19: Ravulizumab has been entered in to clinical trials that aim to determine its ability to combat the dysregulated immune response that drives organ damage (lung and other organs) in patients with severe COVID-19.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Like 6884, ravulizumab binds to complement component C5 thus inhibiting the production of C5a and the membrane attack complex. This mechanism blocks complement-mediated hemolysis. The terminal half-life of free ravulizumab is 25~ days, and for C5-bound ravulizumab it is ~13 days [PMID:29649283]. The corresponding values for eculizumab are ~27 days and  ~4 days for the free and C5-bound antibody.

> <PUBCHEM_SUBSTANCE_SYNONYM>
ravulizumab
ALXN-1210
ALXN1210
ravulizumab-cwvz
Ultomiris
GTPL10168

> <PUBCHEM_XREF_EXT_ID>
10168

> <PUBCHEM_PUBMED_ID>
30510079
29649283
30171081
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10168

$$$$
387271627
  -OEChem-02172115172D

268275  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  1  0  0  0  0
 12 13  1  0  0  0  0
 13 14  1  0  0  0  0
 14 15  1  0  0  0  0
 15 16  1  0  0  0  0
 16 17  2  0  0  0  0
 16 18  1  0  0  0  0
 18 19  1  0  0  0  0
 19 20  1  0  0  0  0
 19 21  1  0  0  0  0
 21 22  2  0  0  0  0
 21 23  1  0  0  0  0
 19 24  1  0  0  0  0
 24 25  1  0  0  0  0
 25 26  1  0  0  0  0
 26 27  2  0  0  0  0
 26 28  1  0  0  0  0
 28 29  1  0  0  0  0
 29 30  1  0  0  0  0
 30 31  1  0  0  0  0
 31 32  1  0  0  0  0
 32 33  1  0  0  0  0
 33 34  1  0  0  0  0
 34 35  1  0  0  0  0
 35 36  1  0  0  0  0
 36 37  1  0  0  0  0
 37 38  1  0  0  0  0
 38 39  1  0  0  0  0
 39 40  1  0  0  0  0
 40 41  1  0  0  0  0
 41 42  1  0  0  0  0
 42 43  1  0  0  0  0
 43 44  1  0  0  0  0
 44 45  1  0  0  0  0
 45 46  1  0  0  0  0
 46 47  1  0  0  0  0
 47 48  1  0  0  0  0
 48 49  1  0  0  0  0
 49 50  1  0  0  0  0
 50 51  1  0  0  0  0
 51 52  1  0  0  0  0
 52 53  1  0  0  0  0
 53 54  1  0  0  0  0
 54 55  1  0  0  0  0
 55 56  1  0  0  0  0
 56 57  1  0  0  0  0
 57 58  1  0  0  0  0
 58 59  1  0  0  0  0
 59 60  1  0  0  0  0
 60 61  1  0  0  0  0
 61 62  1  0  0  0  0
 62 63  1  0  0  0  0
 63 64  1  0  0  0  0
 64 65  1  0  0  0  0
 65 66  1  0  0  0  0
 66 67  1  0  0  0  0
 67 68  1  0  0  0  0
 68 69  1  0  0  0  0
 69 70  1  0  0  0  0
 70 71  1  0  0  0  0
 71 72  1  0  0  0  0
 72 73  1  0  0  0  0
 73 74  1  0  0  0  0
 74 75  1  0  0  0  0
 75 76  1  0  0  0  0
 76 77  1  0  0  0  0
 77 78  1  0  0  0  0
 78 79  1  0  0  0  0
 79 80  1  0  0  0  0
 80 81  1  0  0  0  0
 81 82  1  0  0  0  0
 82 83  1  0  0  0  0
 83 84  1  0  0  0  0
 84 85  1  0  0  0  0
 85 86  1  0  0  0  0
 86 87  1  0  0  0  0
 87 88  1  0  0  0  0
 88 89  1  0  0  0  0
 89 90  1  0  0  0  0
 90 91  1  0  0  0  0
 91 92  1  0  0  0  0
 92 93  1  0  0  0  0
 93 94  1  0  0  0  0
 94 95  1  0  0  0  0
 95 96  1  0  0  0  0
 96 97  1  0  0  0  0
 97 98  1  0  0  0  0
 98 99  1  0  0  0  0
 99100  1  0  0  0  0
100101  1  0  0  0  0
101102  1  0  0  0  0
102103  1  0  0  0  0
103104  2  0  0  0  0
103105  1  0  0  0  0
105106  1  0  0  0  0
106107  1  0  0  0  0
107108  1  0  0  0  0
108109  1  0  0  0  0
109110  1  0  0  0  0
110111  1  0  0  0  0
110112  1  0  0  0  0
112113  2  0  0  0  0
112114  1  0  0  0  0
110115  1  0  0  0  0
115116  1  0  0  0  0
116117  2  0  0  0  0
116118  1  0  0  0  0
118119  1  0  0  0  0
118120  1  0  0  0  0
120121  1  0  0  0  0
121122  1  0  0  0  0
122123  1  0  0  0  0
123124  1  0  0  0  0
124125  1  0  0  0  0
120125  1  0  0  0  0
118126  1  0  0  0  0
126127  1  0  0  0  0
127128  2  0  0  0  0
127129  1  0  0  0  0
129130  1  0  0  0  0
129131  1  0  0  0  0
131132  1  0  0  0  0
132133  1  0  0  0  0
133134  1  0  0  0  0
129134  1  0  0  0  0
134135  1  0  0  0  0
135136  2  0  0  0  0
135137  1  0  0  0  0
137138  1  0  0  0  0
137139  1  0  0  0  0
139140  1  0  0  0  0
140141  2  0  0  0  0
140142  1  0  0  0  0
142143  1  0  0  0  0
142144  1  0  0  0  0
144145  1  0  0  0  0
145146  2  0  0  0  0
145147  1  0  0  0  0
147148  1  0  0  0  0
147149  1  0  0  0  0
149150  1  0  0  0  0
150151  2  0  0  0  0
151152  1  0  0  0  0
152153  1  0  0  0  0
152154  1  0  0  0  0
154155  1  0  0  0  0
150155  1  0  0  0  0
155156  2  0  0  0  0
156157  1  0  0  0  0
157158  2  0  0  0  0
158159  1  0  0  0  0
154159  2  0  0  0  0
147160  1  0  0  0  0
160161  1  0  0  0  0
161162  2  0  0  0  0
161163  1  0  0  0  0
163164  1  0  0  0  0
163165  1  0  0  0  0
165166  1  0  0  0  0
166167  2  0  0  0  0
166168  1  0  0  0  0
168169  1  0  0  0  0
168170  1  0  0  0  0
170171  1  0  0  0  0
170172  1  0  0  0  0
170173  1  0  0  0  0
168174  1  0  0  0  0
174175  1  0  0  0  0
175176  2  0  0  0  0
175177  1  0  0  0  0
177178  1  0  0  0  0
177179  1  0  0  0  0
179180  1  0  0  0  0
180181  2  0  0  0  0
180182  1  0  0  0  0
182183  1  0  0  0  0
182184  1  0  0  0  0
184185  1  0  0  0  0
185186  2  0  0  0  0
185187  1  0  0  0  0
187188  1  0  0  0  0
188189  1  0  0  0  0
189190  1  0  0  0  0
190191  1  0  0  0  0
191192  1  0  0  0  0
192193  1  0  0  0  0
192194  1  0  0  0  0
194195  1  0  0  0  0
195196  2  0  0  0  0
195197  1  0  0  0  0
192198  1  0  0  0  0
198199  2  0  0  0  0
198200  1  0  0  0  0
200201  1  0  0  0  0
201202  1  0  0  0  0
201203  1  0  0  0  0
203204  2  0  0  0  0
203205  1  0  0  0  0
205206  1  0  0  0  0
206207  1  0  0  0  0
206208  1  0  0  0  0
208209  2  0  0  0  0
208210  1  0  0  0  0
210211  1  0  0  0  0
211212  1  0  0  0  0
211213  1  0  0  0  0
213214  2  0  0  0  0
213215  1  0  0  0  0
215216  1  0  0  0  0
216217  1  0  0  0  0
216218  1  0  0  0  0
218219  2  0  0  0  0
218220  1  0  0  0  0
182220  1  0  0  0  0
216221  1  0  0  0  0
221222  1  0  0  0  0
222223  1  0  0  0  0
223224  2  0  0  0  0
224225  1  0  0  0  0
225226  2  0  0  0  0
226227  1  0  0  0  0
222227  2  0  0  0  0
211228  1  0  0  0  0
228229  1  0  0  0  0
229230  1  0  0  0  0
230231  1  0  0  0  0
231232  1  0  0  0  0
232233  2  0  0  0  0
232234  1  0  0  0  0
206235  1  0  0  0  0
235236  1  0  0  0  0
236237  1  0  0  0  0
237238  2  0  0  0  0
237239  1  0  0  0  0
201240  1  0  0  0  0
240241  1  0  0  0  0
240242  1  0  0  0  0
179243  1  0  0  0  0
177244  1  0  0  0  0
244245  1  0  0  0  0
245246  2  0  0  0  0
245247  1  0  0  0  0
163248  1  0  0  0  0
248249  1  0  0  0  0
249250  1  0  0  0  0
250251  2  0  0  0  0
251252  1  0  0  0  0
252253  2  0  0  0  0
253254  1  0  0  0  0
249254  2  0  0  0  0
252255  1  0  0  0  0
142256  1  0  0  0  0
256257  1  0  0  0  0
257258  1  0  0  0  0
258259  2  0  0  0  0
258260  1  0  0  0  0
137261  1  0  0  0  0
261262  1  0  0  0  0
262263  1  0  0  0  0
263264  2  0  0  0  0
264265  1  0  0  0  0
265266  2  0  0  0  0
266267  1  0  0  0  0
262267  2  0  0  0  0
265268  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
387271627

> <PUBCHEM_SUBSTANCE_VERSION>
3

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10404

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Zilucoplan (RA101495) is a synthetic, macrocyclic peptide that blocks the cleavage of complement C5 into C5a and C5b which occurs as a consequence of activation of the classical, alternative, or lectin pathways. This mechanism of action inhibits formation of the membrane attack complex (MAC). It was developed by RaPharma for the treatment of tissue-based complement-mediated disorders.
Clinical use: Zilucoplan has progressed to Phase 2 clinical evaluation in paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis [PMID:30762205]. Click here to link to ClinicalTrials.gov's full list of zilucoplan trials. In response to the SARS-CoV-2 pandemic plans are underway to evaluate zilucoplan in COVID-19 patients, as part of the UK's Accelerating COVID-19 Research and Development (ACCORD) initiative (June 2020).  ACCORD aims to fast-track potential treatments for COVID-19 through early-stage clinical trials . In this setting researchers would aim to determine if the anti-inflammatory action of terminal complement activation has efficacy to reduce mortality in patients with severe COVID-19.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Zilucoplan is a terminal complement inhibitor that has demonstrated promising clinical efficacy in patients with autoimmune myasthenia gravis . The functional effect of zilucoplan (i.e. inhibition of membrane attack complex formation) is comparable with the effect of the anti-C5 monoclonal eculizumab that is an approved PNH and generalized myasthenia gravis therapeutic.

> <PUBCHEM_SUBSTANCE_SYNONYM>
zilucoplan
RA101495
GTPL10404

> <PUBCHEM_XREF_EXT_ID>
10404

> <PUBCHEM_PUBMED_ID>
30762205
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10404

> <PUBCHEM_CID_ASSOCIATIONS>
133083018  1

$$$$
135651229
  -OEChem-02172115172D

 50 54  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  2  0  0  0  0
 11 12  1  0  0  0  0
 12 13  2  0  0  0  0
 13 14  1  0  0  0  0
  9 14  2  0  0  0  0
 12 15  1  0  0  0  0
 15 16  1  0  0  0  0
 16 17  2  0  0  0  0
 17 18  1  0  0  0  0
 18 19  2  0  0  0  0
 19 20  1  0  0  0  0
 15 20  2  0  0  0  0
 19 21  1  0  0  0  0
 21 22  2  3  0  0  0
 22 23  1  0  0  0  0
 23 24  1  0  0  0  0
 24 25  1  0  0  0  0
 25 26  1  0  0  0  0
 18 26  1  0  0  0  0
 26 27  1  0  0  0  0
 27 28  1  0  0  0  0
 28 29  1  0  0  0  0
 28 30  1  0  0  0  0
 22 31  1  0  0  0  0
 31 32  2  0  0  0  0
 31 33  1  0  0  0  0
 33 34  1  0  0  0  0
 34 35  1  0  0  0  0
 35 36  2  0  0  0  0
 36 37  1  0  0  0  0
 37 38  2  0  0  0  0
 38 39  1  0  0  0  0
 34 39  2  0  0  0  0
 37 40  1  0  0  0  0
 40 41  2  0  0  0  0
 40 42  1  0  0  0  0
 42 43  1  0  0  0  0
 43 44  2  0  0  0  0
 44 45  1  0  0  0  0
 45 46  2  0  0  0  0
 46 47  1  0  0  0  0
 43 47  1  0  0  0  0
 47 48  1  0  0  0  0
 48 49  1  0  0  0  0
 49 50  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
135651229

> <PUBCHEM_SUBSTANCE_VERSION>
9

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
801

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Cenicriviroc is a C-C motif chemokine receptor-2/5 (CCR2/5) antagonist. It was primarily designed for anti-inflammatory potential, but it also has antifibrotic effects, and acts as an entry inhibitor for HIV infection (via CCR5 antagonism).
Clinical use: Cenicriviroc has been evaluated in Phase 2 clinical trial as a treatment for liver fibrosis, and has shown promising improvements in fibrosis in patients in the experimental arm of the study [PMID:28833331]. A Phase 3 trial is underway for this indication- see NCT03028740. Click here to link to ClinicalTrials.gov's full list of cenicriviroc trials.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Cenicriviroc is a CCR2/5 antagonist that was primarily designed for anti-inflammatory potential.

> <PUBCHEM_SUBSTANCE_SYNONYM>
cenicriviroc
(5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(S)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide
TAK 652
TAK-652
TAK652
TBR-652
GTPL801

> <PUBCHEM_XREF_EXT_ID>
801

> <PUBCHEM_PUBMED_ID>
16251299
28833331
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=801

> <PUBCHEM_CID_ASSOCIATIONS>
68533031  1

$$$$
178102653
  -OEChem-02172115172D

 85 88  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  3  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  6  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
  3 10  1  0  0  0  0
 10 12  1  0  0  0  0
  6 13  1  0  0  0  0
 13 14  1  0  0  0  0
 14 15  1  0  0  0  0
 14 16  1  0  0  0  0
 16 17  1  0  0  0  0
 16 18  1  0  0  0  0
 18 19  1  0  0  0  0
 19 20  2  0  0  0  0
 19 21  1  0  0  0  0
 21 22  1  0  0  0  0
 21 23  1  0  0  0  0
 23 24  1  0  0  0  0
 24 25  1  0  0  0  0
 25 26  1  0  0  0  0
 26 27  1  0  0  0  0
 21 27  1  0  0  0  0
 27 28  1  0  0  0  0
 28 29  2  0  0  0  0
 28 30  1  0  0  0  0
 30 31  2  0  0  0  0
 30 32  1  0  0  0  0
 32 33  1  0  0  0  0
 32 34  1  0  0  0  0
 34 35  1  0  0  0  0
 35 36  1  0  0  0  0
 35 37  1  0  0  0  0
 37 38  1  0  0  0  0
 38 39  1  0  0  0  0
 39 40  1  0  0  0  0
 32 39  1  0  0  0  0
 39 41  1  0  0  0  0
 35 42  1  0  0  0  0
 42 43  1  0  0  0  0
 43 44  1  0  0  0  0
 43 45  1  0  0  0  0
 45 46  1  0  0  0  0
 43 47  1  0  0  0  0
 47 48  2  0  0  0  0
 48 49  1  0  0  0  0
 49 50  2  0  0  0  0
 50 51  1  0  0  0  0
 51 52  2  0  0  0  0
 52 53  1  0  0  0  0
 53 54  1  0  0  0  0
 53 55  1  0  0  0  0
 55 56  1  0  0  0  0
 56 57  1  0  0  0  0
 56 58  1  0  0  0  0
 58 59  2  0  0  0  0
 58 60  1  0  0  0  0
 60 61  1  0  0  0  0
 60 62  1  0  0  0  0
 62 63  1  0  0  0  0
 62 64  1  0  0  0  0
 64 65  2  0  0  0  0
 65 66  1  0  0  0  0
 66 67  1  0  0  0  0
 66 68  1  0  0  0  0
 68 69  2  0  0  0  0
 68 70  1  0  0  0  0
 16 70  1  0  0  0  0
 66 71  1  0  0  0  0
 64 72  1  0  0  0  0
 62 73  1  0  0  0  0
 60 74  1  0  0  0  0
 74 75  1  0  0  0  0
 56 76  1  0  0  0  0
 53 77  1  0  0  0  0
 47 78  1  0  0  0  0
 14 79  1  0  0  0  0
 48 80  1  0  0  0  0
 49 81  1  0  0  0  0
 50 82  1  0  0  0  0
 51 83  1  0  0  0  0
 52 84  1  0  0  0  0
 65 85  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178102653

> <PUBCHEM_SUBSTANCE_VERSION>
12

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
6031

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Sirolimus is a macrolide produced by the bacteria Streptomyces hygroscopicus. It has potent immunosuppressive and antiproliferative properties.
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Sirolimus is used for prophylaxis of renal transplant rejection [PMID:9399599][PMID:10711524], and may be used in combination with cyclosporin A. In June 2015 the US FDA approved sirolimus for the treatment of lymphangioleiomyomatosis, a rare proliferative but benign lung disease [PMID:21410393].
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).

> <PUBCHEM_SUBSTANCE_SYNONYM>
sirolimus
AY-22989
Rapamune
rapamycin
WY-090217
GTPL6031

> <PUBCHEM_XREF_EXT_ID>
6031

> <PUBCHEM_PUBMED_ID>
7539137
22037377
7809080
29143192
9933627
25487801
9399599
10711524
21410393
9857082
23398362
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6031

> <PUBCHEM_CID_ASSOCIATIONS>
5284616  1

$$$$
223366205
  -OEChem-02172115172D

 41 43  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  4  6  1  0  0  0  0
  4  7  1  0  0  0  0
  2  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
  9 11  1  0  0  0  0
 11 12  1  0  0  0  0
 11 13  1  0  0  0  0
 11 14  1  0  0  0  0
  9 15  1  0  0  0  0
 15 16  2  0  0  0  0
 15 17  1  0  0  0  0
 17 18  1  0  0  0  0
 18 19  1  0  0  0  0
 19 20  1  0  0  0  0
 19 21  1  0  0  0  0
 21 22  1  0  0  0  0
 21 23  1  0  0  0  0
 23 24  1  0  0  0  0
 17 23  1  0  0  0  0
 23 25  1  0  0  0  0
 25 26  2  0  0  0  0
 25 27  1  0  0  0  0
 27 28  1  0  0  0  0
 28 29  1  0  0  0  0
 29 30  2  0  0  0  0
 29 31  1  0  0  0  0
 31 32  2  0  0  0  0
 31 33  1  0  0  0  0
 28 34  1  0  0  0  0
 34 35  1  0  0  0  0
 35 36  1  0  0  0  0
 36 37  1  0  0  0  0
 37 38  1  0  0  0  0
 35 38  1  0  0  0  0
 21 39  1  0  0  0  0
 19 39  1  0  0  0  0
 39 40  1  0  0  0  0
 39 41  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
223366205

> <PUBCHEM_SUBSTANCE_VERSION>
7

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
7876

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Boceprevir is an active site-binding inhibitor of the main protease (nonstructural protein 3, NS3) of hepatitis C virus (HCV). A patent claims boceprevir for repurposing as cathepsin A modulator . More recently it has been reported to inhibit the 3CL protease (Mpro) of several coronaviruses, including SARS-CoV-2 Mpro . An alternative enantiomer is reported in the SARS-CoV-2 Mpro/boceprevir crystal structure 6WNP, which maps to PubChem CID 71316139.
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Oral boceprevir was approved for use in combination with injectable peginterferon alfa-2b and ribavirin to treat chronic hepatitis C (HCV) genotype 1 infection. It was witdrawn from both the US and European markets in response to advances in the treatment practices for chronic HCV infection that led to reduced demand for boceprevir (Victrelis).

> <PUBCHEM_SUBSTANCE_SYNONYM>
boceprevir
(1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
EBP-520
EBP520
SCH-503034
SCH503034
Victrelis
GTPL7876

> <PUBCHEM_XREF_EXT_ID>
7876

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7876

> <PUBCHEM_CID_ASSOCIATIONS>
10324367  1

$$$$
385612237
  -OEChem-02172115172D

 39 45  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  2  0  0  0  0
  3  4  1  0  0  0  0
  4  5  2  0  0  0  0
  5  6  1  0  0  0  0
  2  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  2  0  0  0  0
  9 10  1  0  0  0  0
 10 11  2  0  0  0  0
 11 12  1  0  0  0  0
  7 12  2  0  0  0  0
 11 13  1  0  0  0  0
 13 14  1  0  0  0  0
 14 15  1  0  0  0  0
 15 16  1  0  0  0  0
 16 17  2  0  0  0  0
 10 17  1  0  0  0  0
 17 18  1  0  0  0  0
 18 19  2  0  0  0  0
 19 20  1  0  0  0  0
 20 21  2  0  0  0  0
 16 21  1  0  0  0  0
  4 22  1  0  0  0  0
 22 23  1  0  0  0  0
 23 24  1  0  0  0  0
 24 25  2  0  0  0  0
 25 26  1  0  0  0  0
 26 27  2  0  0  0  0
 27 28  1  0  0  0  0
 23 28  2  0  0  0  0
 27 29  1  0  0  0  0
 29 30  1  0  0  0  0
 30 31  1  0  0  0  0
 31 32  1  0  0  0  0
 31 33  1  0  0  0  0
 33 34  1  0  0  0  0
 26 34  1  0  0  0  0
 31 35  1  0  0  0  0
 35 36  1  0  0  0  0
 36 37  1  0  0  0  0
 37 38  1  0  0  0  0
 38 39  1  0  0  0  0
 35 39  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
385612237

> <PUBCHEM_SUBSTANCE_VERSION>
2

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10478

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Bemcentinib (BGB324, R428) is a potent, selective and orally active AXL receptor tyrosine kinase inhibitor that was discovered by Rigel as R428 [PMID:20145120] and which is being developed by BergenBio for anti-cancer potential [PMID:26555154].
Clinical use: BGB324 has advanced to Phase 2 clinical evaluations in a variety of solid tumour types and in leukemia . Click here to link to ClinicalTrials.gov's full list of BGB324 studies.In response to the SARS-CoV-2 pandemic plans are underway to evaluate bemcentinib in COVID-19 patients, as part of the UK's Accelerating COVID-19 Research and Development (ACCORD) initiative (June 2020).  ACCORD aims to fast-track potential treatments for COVID-19 through early-stage clinical trials . In this setting researchers would aim to determine if the anti-inflammatory action of AXL-inhibition has efficacy to reduce mortality in patients with severe COVID-19.

> <PUBCHEM_SUBSTANCE_SYNONYM>
bemcentinib
BGB-324
BGB324
R-428
R428
GTPL10478

> <PUBCHEM_XREF_EXT_ID>
10478

> <PUBCHEM_PUBMED_ID>
20145120
26555154

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10478

> <PUBCHEM_CID_ASSOCIATIONS>
46215462  1

$$$$
405067325
  -OEChem-02172115172D

 35 37  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  3  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  5  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  2  0  0  0  0
  3  5  1  0  0  0  0
  5  6  1  0  0  0  0
  5  7  1  0  0  0  0
  7  8  1  0  0  0  0
  7  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  2  0  0  0  0
 10 12  1  0  0  0  0
 12 13  1  0  0  0  0
 13 14  2  0  0  0  0
 14 15  1  0  0  0  0
 15 16  2  0  0  0  0
 16 17  1  0  0  0  0
 12 17  2  0  0  0  0
 15 18  1  0  0  0  0
 18 19  1  0  0  0  0
 19 20  2  0  0  0  0
 20 21  1  0  0  0  0
 21 22  2  0  0  0  0
 22 23  1  0  0  0  0
 18 23  2  0  0  0  0
 21 24  1  0  0  0  0
  7 25  1  0  0  0  0
  5 26  1  0  0  0  0
 26 27  1  0  0  0  0
 27 28  1  0  0  0  0
 28 29  2  0  0  0  0
 29 30  1  0  0  0  0
 30 31  2  0  0  0  0
 31 32  1  0  0  0  0
 27 32  2  0  0  0  0
 31 33  1  0  0  0  0
 33 34  2  0  0  0  0
 33 35  1  0  0  0  0
M  CHG  2  21   1  24  -1
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
405067325

> <PUBCHEM_SUBSTANCE_VERSION>
1

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10732

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Otamixaban (FXV673) is an anticoagulant that was originally reported by Aventis Pharmaceuticals (Sanofi) [PMID:12039587]. It is a potent and selective direct inhibitor of coagulation factor Xa that is delivered intravenously. The INN record stipulates the (2R,3R) configuration. Virtual docking studies suggest that otamixaban may bind to the serine protease TMPRSS2 , which is linked to host cell entry by a number of viruses, in particular influenza viruses and respiratory viruses such as SARS-CoV-2. Inhibition of TMPRSS2 is being examined for antiviral activity. The TMPRSS2 inhibitory potential and/or antiviral activity of otamixaban have not yet been determined.
Clinical use: FXV673 has completed Phase 3 clinical evaluation, but it was not progressed due to an unsatisfactory risk-benefit profile.

> <PUBCHEM_SUBSTANCE_SYNONYM>
otamixaban
methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate
compound 9c [PMID: 12039587]
FXV-673
FXV673
XRP-0673
XRP0673
GTPL10732

> <PUBCHEM_XREF_EXT_ID>
10732

> <PUBCHEM_PUBMED_ID>
12039587

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10732

> <PUBCHEM_CID_ASSOCIATIONS>
5496659  1

$$$$
178103773
  -OEChem-02172115172D

 23 24  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  2  0  0  0  0
 12 13  1  0  0  0  0
 13 14  2  0  0  0  0
 14 15  1  0  0  0  0
 10 15  2  0  0  0  0
 15 16  1  0  0  0  0
 16 17  2  0  0  0  0
 17 18  1  0  0  0  0
 18 19  2  0  0  0  0
 14 19  1  0  0  0  0
 18 20  1  0  0  0  0
  8 21  1  0  0  0  0
  4 22  1  0  0  0  0
 22 23  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178103773

> <PUBCHEM_SUBSTANCE_VERSION>
13

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
7198

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Hydroxychloroquine (HCQ) is a 4-aminoquinoline and used primarily as an antimalarial drug.The approved drug is a racemic mixture and we show the chemical structure without stereochemistry to represent the mixture. The non-isomeric structure is also represented in the PubChem, ChEMBL and ChEBI entries listed in the links table below, while the two enantiomers forming the racemate are represented by PubChem CID 178395 and PubChem CID 178396.The marketed formulations contain hydroxychloroquine sulfate (PubChem CID 3044369).Activity at non-malarial protein targets:Although this drug has direct effects on survival of the malaria parasite it also appears to be an antagonist of two of the human TOLL-like receptors (TLR7 and TLR9). Antagonism of these receptors is likely related to the anti-inflammatory action of this drug in auto-immune diseases. Some patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis are prescribed HCQ [PMID:23778483].   Activity against SARS-CoV-2:Hydroxychloroquine exhibits in vitro antiviral activity against both the original SARS coronavirus (SARS-CoV) [PMID:16640347] and SARS-CoV-2 which emerged in 2019 .   Extreme caution must be taken when condisering using hydroxychloroquine (HCQ) as it has severe cardiac adverse effects, and in addition its distribution to lung tissue is unknown. There was much hype around repositioning HCQ to treat COVID-19. But this was based on preliminary evidence from a cohort of COVID-19 patients in a VERY small study [PMID:32205204] and anecdotal evidence that patients taking HCQ for other diseases fared better if they developed COVID-19. There was also a lot of controversy around some of the larger scale trials, particularly of how they were carried out, and/or how they were reported or published. Results from subsequent well run, well powered, large scale RCTs does not support any clinical benefit from HCQ in COVID-19 patients. HCQ may even pose an acceptable risk of harm in COVID19 patients [PMID:32392282]. Derek Lowe's 'In the PIPELINE' blog (https://bit.ly/31C7DT1) provides a systematic and considered anaylsis of the (lack of) potential for hydroxychloroquine/chloroquine for COVID-19.
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_who - Substance is included in WHO Essential Medicines List.
Clinical use: Hydroxychloroquine is used to treat or prevent malaria, and is also used to treat discoid lupus erythematosus and rheumatoid arthritis.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Antagonism of TOLL-like receptors TLR7 and TLR9 is likely related to the anti-inflammatory action of this drug, as these receptors have been implicated in initiating the inflammatory reaction to 'self' molecules [PMID:20404851].
gtopdb_malaria - Substance is curated in IUPHAR/MMV Guide to Malaria Pharmacology (GtoMPdb).

> <PUBCHEM_SUBSTANCE_SYNONYM>
hydroxychloroquine
2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol
Dolquine
Plaquenil
GTPL7198

> <PUBCHEM_XREF_EXT_ID>
7198

> <PUBCHEM_PUBMED_ID>
20404851
22363211
24342772
32205204
23778483
32392282
16640347
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7198

> <PUBCHEM_CID_ASSOCIATIONS>
3652  1

$$$$
363894189
  -OEChem-02172115172D

 57 59  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 N   0  5  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  3  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  3  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  3  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  5  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0  0  0  0
  2  3  2  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  2  0  0  0  0
 10 11  1  0  0  0  0
 10 12  1  0  0  0  0
 12 13  2  0  0  0  0
 13 14  1  0  0  0  0
  8 14  2  0  0  0  0
 13 15  1  0  0  0  0
 12 16  1  0  0  0  0
 16 17  2  0  0  0  0
 16 18  1  0  0  0  0
 18 19  1  0  0  0  0
 19 20  1  0  0  0  0
 20 21  2  0  0  0  0
 20 22  1  0  0  0  0
 22 23  1  0  0  0  0
 23 24  1  0  0  0  0
 24 25  1  0  0  0  0
 25 26  1  0  0  0  0
 26 27  2  0  0  0  0
 27 28  1  0  0  0  0
 28 29  1  0  0  0  0
 27 30  1  0  0  0  0
 30 31  2  0  0  0  0
 31 32  1  0  0  0  0
 25 32  2  0  0  0  0
 32 33  1  0  0  0  0
 33 34  2  0  0  0  0
 33 35  1  0  0  0  0
 30 36  1  0  0  0  0
 36 37  1  0  0  0  0
 24 38  1  0  0  0  0
 23 39  1  0  0  0  0
 19 40  1  0  0  0  0
 40 41  1  0  0  0  0
 41 42  1  0  0  0  0
 42 43  2  0  0  0  0
 42 44  1  0  0  0  0
 44 45  1  0  0  0  0
 45 46  1  0  0  0  0
 46 47  2  0  0  0  0
 46 48  1  0  0  0  0
 48 49  1  0  0  0  0
 49 50  2  0  0  0  0
 50 51  1  0  0  0  0
 51 52  2  0  0  0  0
 52 53  1  0  0  0  0
 48 53  2  0  0  0  0
 52 54  1  0  0  0  0
 54 55  1  0  0  0  0
 55 56  2  0  0  0  0
 55 57  1  0  0  0  0
M  CHG  4   1  -1   2   1  33   1  35  -1
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
363894189

> <PUBCHEM_SUBSTANCE_VERSION>
4

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
9895

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Compound 1 is a photoactivatable alpha5beta1 integrin ligand [PMID:29774654]. Structurally it is a selective alpha5beta1 integrin ligand (a peptidomimetic of the RGD adhesive motif found in several extracellular matrix (ECM) proteins) linked to a 3-(4,5-Dimethoxy-2-nitrophenyl)-2-butyl ester (DMNPB) photocleavable chromophore. When intact, the compound is unable to bind the integrin, but upon exposure to light the chromophore is cleaved and the ligand then behaves as an antagonist of alpha5beta1 interaction with ECM substrates. The photactivation of compound 1 allows precise, in situ, dose-responsive and temporal study of the role played by alpha5beta1 integrin-dependent processes in cell adhesion and migration.alpha5beta1 integrin is a molecular target that plays recognised roles in tumour angiogenesis and cancer cell migration and metastasis [PMID:28877984][PMID:27613837], that is being expoilted for clinical utility in cancer indications [PMID:29155160][PMID:27255534][PMID:28215671]. alpha5beta1 may also be an immune system/inflammation relevant target [PMID:27918306][PMID:27391025].

> <PUBCHEM_SUBSTANCE_SYNONYM>
compound 1 [Vakkeel et al., 2018]
GTPL9895

> <PUBCHEM_XREF_EXT_ID>
9895

> <PUBCHEM_PUBMED_ID>
29774654
28877984
28215671
27918306
27613837
27255534
27391025
29155160

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9895

> <PUBCHEM_CID_ASSOCIATIONS>
133081967  1

$$$$
178102314
  -OEChem-02172115172D

 37 41  0     0  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  2  7  1  0  0  0  0
  5  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  2  0  0  0  0
 11 12  1  0  0  0  0
 12 13  2  0  0  0  0
 13 14  1  0  0  0  0
  9 14  2  0  0  0  0
 12 15  1  0  0  0  0
 15 16  2  0  0  0  0
 15 17  1  0  0  0  0
 17 18  1  0  0  0  0
 18 19  1  0  0  0  0
 19 20  2  0  0  0  0
 20 21  1  0  0  0  0
 21 22  2  0  0  0  0
 22 23  1  0  0  0  0
 18 23  2  0  0  0  0
 22 24  1  0  0  0  0
 24 25  1  0  0  0  0
 25 26  1  0  0  0  0
 26 27  2  0  0  0  0
 27 28  1  0  0  0  0
 28 29  2  0  0  0  0
 29 30  1  0  0  0  0
 25 30  2  0  0  0  0
 29 31  1  0  0  0  0
 31 32  1  0  0  0  0
 32 33  2  0  0  0  0
 33 34  1  0  0  0  0
 34 35  2  0  0  0  0
 35 36  1  0  0  0  0
 31 36  2  0  0  0  0
 21 37  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178102314

> <PUBCHEM_SUBSTANCE_VERSION>
10

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
5687

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Imatinib is a Type-2 kinase inhibitor. Its main inhibitory activity is against ABL kinase, but it has significant action at secondary targets including platelet-derived growth factor receptor (PDGFR) and stem cell growth factor receptor (KIT).Coronavirus: imatinib is reported to block Spike protein-induced SARS-CoV and MERS-CoV fusion in vitro [PMID:29557770], potentially by blocking Abl2 at the endosomal membrane and disrupting the actin dynamics that are required for virus-host fusion [PMID:27466418]. It will be informative to determine if this holds true for SARS-CoV-2, and whether re-purposing of imatinib and/or newer Abl kinase inhibitors (dasatinib, bosutinib, ponatinib, nilotinib) could be a viable strategy against COVID-19. This approach would likely to be most effective during the early stage of infection.
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_who - Substance is included in WHO Essential Medicines List.
Clinical use: Used in the treatment of multiple cancers including chronic myelogenous leukemia and gastrointestinal stromal tumours (GIST). Adjuvant imatinib is recommended for KIT-mutated GISTs. The clinically administered form is the Imatinib mesilate (mesylate) salt (PubChem CID 123596).Generic imatinib mesylate tablets were approved by the US FDA in December 2015, as therapeutic equivalents of Novartis' original Gleevec.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: The KIT inhibiting action of imatinib inhibits SCF-mediated effects of cord blood mast cells (CBMC) such as survival, chemotaxis, and adhesion [PMID:12960256]. Attenuating KIT activation using imatinib shows efficacy in either chronic allergen-induced airway inflammation and remodeling [PMID:21293142] or hypereosinophilic disorders [PMID:21641642].

> <PUBCHEM_SUBSTANCE_SYNONYM>
imatinib
N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide
CGP 57148
Gleevec
Glivec
STI571
GTPL5687

> <PUBCHEM_XREF_EXT_ID>
5687

> <PUBCHEM_PUBMED_ID>
21641642
22037377
23899692
22037378
21095574
17376680
29557770
27466418
12960256
21293142
23398362
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687

> <PUBCHEM_CID_ASSOCIATIONS>
5291  1

$$$$
178103466
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
178103466

> <PUBCHEM_SUBSTANCE_VERSION>
11

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
6884

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Eculizumab is a humanized monoclonal antibody targeting terminal complement activation, by binding to complement component C5 and inhibiting the production of C5a [PMID:17989688]. It is the first approved therapy for paroxysmal nocturnal hemoglobinuria.Eculizumab's developers, Alexion Pharmaceuticals have developed a next-generation version of eculizumab called ravulizumab (ALXN1210; FDA approved in December 2018), that has a longer circulating half-life than the originator, which allows for monthly dosing.The evidence confirming C5, C5a and the C5a receptor as anti-inflammatory and anti-cancer drug targets is reviewed by Horiuchi  and Tsukamoto (2016) [PMID:29259684].Biosimilars:ABP 959 (Amgen) is in Phase 3 development under the jurisdiction of the Australian New Zealand Clinical Trials Registry (trial ID  ACTRN12616000509460).BOW080 (Epirus Biopharmaceuticals) is in preclinical development- see None of these biosimilars can be FDA approved until Alexion's exclusivity period (due to protection as an orphan drug) expires in March 2019. Eculizumab's patent protection ends in May 2020 (Europe) and March 2021 (US). Hence, Alexion developed the improved agent ravulizumab as a replacement product.
gtopdb_approved - Substance is an approved drug in GtoPdb.
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: Used to treat paroxysmal nocturnal hemoglobinuria (PNH). In the UK, NICE (National Institute for Health and Care Excellence) has approved eculizumab as a treatment for the rare, but fatal blood disorder, atypical haemolytic uraemic syndrome (aHUS). This decision was reached because eculizumab represents a significant innovation for a disease with a high unmet clinical need. Eculizumab treatment is expected to increase life expectancy of aHUS patients by decades. The FDA expanded approval in October 2017, to include treatment of patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody-positive.SARS-C0V-2 and COVID-19: Eculizumab has been entered into clinical trials that aim to determine its ability to combat the dysregulated immune response that drives organ damage (lung and other organs) in patients with severe COVID-19.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: Included in GtoImmuPdb as it acts on the complement system, at the terminal step involved in membrane attack complex formation. The evidence confirming C5, C5a and the C5a receptor as anti-inflammatory drug targets is reviewed by Horiuchi  and Tsukamoto (2016) [PMID:29259684].

> <PUBCHEM_SUBSTANCE_SYNONYM>
eculizumab
h5G1.1
h5G1.1VHC
Soliris
GTPL6884

> <PUBCHEM_XREF_EXT_ID>
6884

> <PUBCHEM_PUBMED_ID>
29649283
17989688
31050279
29259684
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6884

$$$$
315661274
  -OEChem-02172115172D

  0  0  0     0  0  0  0  0  0999 V2000
M  END
> <PUBCHEM_SUBSTANCE_ID>
315661274

> <PUBCHEM_SUBSTANCE_VERSION>
7

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
9195

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Clazakizumab is an investigational, aglycosylated, humanized (from a rabbit parental antibody) monoclonal antibody targeting interleukin-6, with anti-inflammatory potential [PMID:27215204].Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. BLAST peptide sequence analysis reveals identical matches with peptides claimed in patent US8062864 . Results presented in the patent show that the preferred antibodies block interaction of IL-6 with the IL-6 receptor, but no precise binding affinity data is provided.
gtopdb_antibody - GtoPdb identifies this substance as an Antibody
Clinical use: Phase 2 clinical trials in patients with active rheumatoid arthritis (NCT01373151, results reported in [PMID:26138593]), psoriatic arthritis (NCT01490450, results in [PMID:27059799]), cachexia resulting from non-small cell lung cancer [PMID:21995322][PMID:24707881], acute graft versus host disease (GvHD) and oral mucositis caused by head and neck cancer have been completed. Click here to link to ClinicalTrials.gov's list of clazakizumab (ALD518 and BMS-945429) trials.SARS-CoV-2 and COVID-19: Clazakizumab has been entered into clinical trials in patients with COVID-19, with a particular focus on assessing its efficacy in those with life-threatening hyperinflammation.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).

> <PUBCHEM_SUBSTANCE_SYNONYM>
clazakizumab
ALD-518
ALD518
BMS-945429
GTPL9195

> <PUBCHEM_XREF_EXT_ID>
9195

> <PUBCHEM_PUBMED_ID>
24707881
26138593
27215204
27059799
21995322
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9195

$$$$
178103978
  -OEChem-02172115172D

 28 31  0     0  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  2  0  0  0  0
  4  5  1  0  0  0  0
  5  6  2  0  0  0  0
  6  7  1  0  0  0  0
  2  7  2  0  0  0  0
  6  8  1  0  0  0  0
  8  9  1  0  0  0  0
  9 10  2  0  0  0  0
  9 11  1  0  0  0  0
  8 12  2  0  0  0  0
 12 13  1  0  0  0  0
 13 14  2  0  0  0  0
  5 14  1  0  0  0  0
 13 15  1  0  0  0  0
 15 16  1  0  0  0  0
 16 17  2  0  0  0  0
 17 18  1  0  0  0  0
 18 19  2  0  0  0  0
 19 20  1  0  0  0  0
 15 20  2  0  0  0  0
 18 21  1  0  0  0  0
 21 22  1  0  0  0  0
 22 23  2  0  0  0  0
 23 24  1  0  0  0  0
 24 25  2  0  0  0  0
 25 26  1  0  0  0  0
 21 26  2  0  0  0  0
 26 27  1  0  0  0  0
 12 28  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
178103978

> <PUBCHEM_SUBSTANCE_VERSION>
4

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
7406

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Brequinar inhibits dihydroorotate dehydrogenase (DHODH), the fourth enzyme in the de novo pyrimidine biosynthesis pathway [PMID:3019518], and it depletes cells of the precursors that are  critical for RNA and DNA synthesis [PMID:2822596]. It was developed for potential anti-neoplastic activity. The drug exhibits anti-neoplastic activity against refractory solid tumours in preclinical models, with continuous treatment being necessary to effectively deplete pyrimidine pools in the cancer cells and cause tumour inhibition [PMID:2743343].
Clinical use: Brequinar has been advanced to Phase 1/2 clinical evaluation in patiets with acute myeloid leukemia. With the recognition that DHODH inhibitors can have antiviral activity by limiting the supply of host-produced pyrimidines that viruses need to replicate, brequinar is being evaluated in patients with COVID-19 (the clinical manifestation of SARS-CoV-2 infection).

> <PUBCHEM_SUBSTANCE_SYNONYM>
brequinar
6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid
DUP-785
DUP785
NSC 368390
NSC-368390
NSC368390
GTPL7406

> <PUBCHEM_XREF_EXT_ID>
7406

> <PUBCHEM_PUBMED_ID>
2822596
3019518
2743343

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7406

> <PUBCHEM_CID_ASSOCIATIONS>
57030  1

$$$$
328083514
  -OEChem-02172115172D

 33 36  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  3  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  3  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  2  0  0  0  0
  8  9  1  0  0  0  0
  9 10  2  0  0  0  0
 10 11  1  0  0  0  0
  6 11  2  0  0  0  0
  9 12  1  0  0  0  0
 12 13  1  0  0  0  0
 13 14  2  0  0  0  0
 14 15  1  0  0  0  0
 15 16  2  0  0  0  0
 16 17  1  0  0  0  0
 12 17  2  0  0  0  0
 16 18  1  0  0  0  0
 18 19  1  0  0  0  0
 18 20  1  0  0  0  0
 20 21  2  0  0  0  0
 20 22  1  0  0  0  0
 15 22  1  0  0  0  0
  3 23  1  0  0  0  0
 23 24  1  0  0  0  0
 24 25  2  0  0  0  0
 24 26  1  0  0  0  0
 26 27  1  0  0  0  0
 26 28  1  0  0  0  0
 28 29  1  0  0  0  0
 29 30  1  0  0  0  0
 30 31  1  0  0  0  0
 31 32  1  0  0  0  0
 32 33  1  0  0  0  0
 26 33  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
328083514

> <PUBCHEM_SUBSTANCE_VERSION>
8

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
9412

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Brensocatib (formerly AZD7986) is reported as a second generation, oral, selective and reversible inhibitor of dipeptidyl peptidase 1 (DPP1; a.k.a. cathepsin C) [PMID:27690432]. Cathepsin C is required for the activation of proinflammatory neutrophil serine proteases, making this enzyme a drug target whose pharmacological inhibition has potential in the treatment of diseases such as chronic obstructive pulmonary disease (COPD) which is driven in part by excessive neutrophil activation and dysregulated neutrophil elastase activity. The compound was originally developed by AstraZeneca, but is now being progressed by Insmed.
Clinical use: Brensocatib (formerly AZD7986) has completed Phase 1 clinical trials in healthy volunteers (see NCT02303574 and NCT02653872) which confirm on-target effects [PMID:29484635].  Insmed are progressing AZD7986 (re-assigned as INS1007) as an anti-inflammatory approach to treat the cycle of inflammation, infection, and debilitating lung damage that is associated with non-cystic fibrosis bronchiectasis (NCFBE). SARS-CoV-2 and COVID-19: Plans are underway to examine the potential of INS1007 to treat COVID-19-related acute respiratory distress syndrome (ARDS), in the UK STOP-COVID19 clinical trial which is being led from the University of Dundee. The INS1007 arm of the study aims to administer the drug to 150 COVID-19 patients (plus 150 in the placebo arm) across 10 UK hospitals.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: AZD7986 is a cathepsin C inhibitor. Cathepsin C is required for the activation of proinflammatory neutrophil serine proteases, making this enzyme a drug target whose pharmacological inhibition has potential in the treatment of diseases such as chronic obstructive pulmonary disease (COPD) which is driven in part by excessive neutrophil activation and dysregulated neutrophil elastase activity.

> <PUBCHEM_SUBSTANCE_SYNONYM>
brensocatib
(2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide
AZD7986
compound 30
INS 1007
INS1007
GTPL9412

> <PUBCHEM_XREF_EXT_ID>
9412

> <PUBCHEM_PUBMED_ID>
27690432
29484635
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9412

> <PUBCHEM_CID_ASSOCIATIONS>
118253852  1

$$$$
363894154
  -OEChem-02172115172D

 26 28  0     0  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  2  0  0  0  0
  5  6  1  0  0  0  0
  6  7  2  0  0  0  0
  7  8  1  0  0  0  0
  3  8  2  0  0  0  0
  7  9  1  0  0  0  0
  9 10  1  0  0  0  0
 10 11  2  0  0  0  0
 11 12  1  0  0  0  0
 12 13  2  0  0  0  0
 13 14  1  0  0  0  0
  9 14  2  0  0  0  0
 13 15  1  0  0  0  0
 12 16  1  0  0  0  0
 16 17  1  0  0  0  0
 17 18  2  0  0  0  0
 17 19  1  0  0  0  0
 19 20  2  0  0  0  0
 20 21  1  0  0  0  0
 21 22  1  0  0  0  0
 22 23  1  0  0  0  0
 19 23  1  0  0  0  0
 20 24  1  0  0  0  0
 24 25  2  0  0  0  0
 24 26  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
363894154

> <PUBCHEM_SUBSTANCE_VERSION>
5

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
9860

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Vidofludimus (4SC-101) is a small molecule dihydroorotate dehydrogenase (DHOD) inhibitor that was developed for immunosuppressive potential [PMID:20413687]. It has an improved toxicity profile in comparison to the clinically used disease modifying anti-rheumatic drug (DMARD) leflunomide. Since its initial development, vidofludimus has been superceded by IMU-838 which is an orally active polymorph of vidofludimus calcium (PubChem CID: 56944639) [PMID:32361977].SARS-CoV-2 and COVID-19: The target of vidofludimus, DHODH, plays a role in the metabolism of activated T cells and B cells to regulate the inflammatory response. It has been advanced to clinical trial in patients with severe COVID-19, to as attempt to block the release of pro-inflammatory cytokines and temper hyperinflammation in these patients.
Clinical use: Phase 2 clinical trials designed to determine the clinical efficacy of the original formulation, 4SC-101 in inflammatory bowel disease and rheumatoid arthritis have been completed. Published results from the IBD trial NCT00820365 are indicative of clinical efficacy in this indication [PMID:23078909]. Vidofludimus missed the primary endpoint in a Phase 2b RA trial. A new formulation of vidofludimus known as IMU-838 has replaced the original agent, and this is under active evaluation for clinical efficacy in ulcerative colitis, primary sclerosing cholangitis, multiple sclerosis [PMID:32428844] and COVID-19.
gtopdb_immuno - Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb).
GtoImmuPdb Comment: DHODH is a mitochondrial enzyme that is required for pyrimidine biosynthesis and is a molecular target for the treatment of numerous diseases, including autoimmune diseases [PMID:21355448].  DHODH inhibitors exhibit anti-proliferative, anti-inflammatory and immunosuppressive properties (e.g. brequinar has antitumour and immunosuppressive activity and leflunomide is immunosuppressive).

> <PUBCHEM_SUBSTANCE_SYNONYM>
vidofludimus
2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
4SC-101
IMU-838 (vidofludimus calcium)
SC12267
GTPL9860

> <PUBCHEM_XREF_EXT_ID>
9860

> <PUBCHEM_PUBMED_ID>
20413687
20310011
32428844
21355448
23078909
32361977
32020584

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9860

> <PUBCHEM_CID_ASSOCIATIONS>
9820008  1

$$$$
404859162
  -OEChem-02172115172D

 46 49  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 P   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  2  0  0  0  0
  6  8  1  0  0  0  0
  8  9  1  0  0  0  0
  8 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  2  0  0  0  0
 11 13  1  0  0  0  0
 13 14  1  0  0  0  0
 14 15  1  0  0  0  0
 15 16  2  0  0  0  0
 16 17  1  0  0  0  0
 17 18  2  0  0  0  0
 18 19  1  0  0  0  0
 14 19  2  0  0  0  0
 11 20  1  0  0  0  0
 20 21  1  0  0  0  0
 21 22  1  0  0  0  0
 22 23  1  0  0  0  0
 22 24  1  0  0  0  0
 24 25  1  0  0  0  0
 25 26  1  0  0  0  0
 26 27  1  0  0  0  0
 26 28  1  0  0  0  0
 28 29  1  0  0  0  0
 22 28  1  0  0  0  0
 28 30  1  0  0  0  0
 26 31  1  0  0  0  0
 25 32  1  0  0  0  0
 32 33  3  0  0  0  0
 25 34  1  0  0  0  0
 34 35  2  0  0  0  0
 35 36  1  0  0  0  0
 36 37  2  0  0  0  0
 37 38  1  0  0  0  0
 34 38  1  0  0  0  0
 38 39  1  0  0  0  0
 39 40  2  0  0  0  0
 40 41  1  0  0  0  0
 41 42  2  0  0  0  0
 37 42  1  0  0  0  0
 42 43  1  0  0  0  0
  8 44  1  0  0  0  0
  3 45  1  0  0  0  0
 45 46  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
404859162

> <PUBCHEM_SUBSTANCE_VERSION>
4

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10715

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: Remdesivir (GS-5734) is a nucleotide analogue drug that was developed by Gilead Sciences for antiviral potential, in particular for anti-Ebola and anti-Marburg virus activity [PMID:28124907]. It is a prodrug whose active metabolite is GS-441524 (PubChem CID: 44468216).  The compound's 1'-CN group and C-linked nucleobase ensure optimal anti-Ebola potency and selectivity against host polymerase enzymes. Remdesivir has broad-spectrum activity against several viral families such as filoviruses, paramyxoviruses, and coronaviruses, and including the SARS and MERS coronaviruses (CoVs), endemic circulating human CoVs, and against SARS-CoV-2 [PMID:29511076][PMID:28659436][PMID:32284326]. The first patient to test positive for SARS-CoV-2 in the US was treated with i.v. remdesivir (using compassionate use of an investigational therapy prescribing) and his clinical condition improved significantly within the next 24h without observation of adverse effects [PMID:32004427].
gtopdb_approved - Substance is an approved drug in GtoPdb.
Clinical use: Remdesivir (GS-5734) must be administered by intravenous (i.v.) infusion. Remdesivir progressed to Phase 2 evaluation in Ebola infected patients. It is to be evaluated for efficacy in the treatment of the novel coronavirus (SARS-CoV-2) infection COVID-19, with 4 Phase 3 trials registered on ClinicalTrials.gov as of early March 2020. Grein et al. published results from short-term compassionate-use remdesivir in hospitalised COVID-19 patients (receiving invasive ventilation or ECMO) in the NEJM in April 2020 [PMID:32275812]. Whilst this study indicated some clinical benefit, and detected no additional safety signals, it was not powered to conclusively determine clinical efficacy. The study did not measure the effect of remdesivir on viral load, and it was not placebo-controlled. In some cases remdesivir seems to shorten the time to recovery. Despite limited data on efficacy, the FDA granted full approval in October 2020, for the treatment of hospitalised COVID-19 patients. This was quite unexpected because the FDA based their decision on data from a set of studies that were not suitably designed or controlled, and gave mixed results. It remains the case that larger controlled trials are needed.

> <PUBCHEM_SUBSTANCE_SYNONYM>
remdesivir
2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
compound 4b [PMID: 28124907]
GS-5734
GS5734
Veklury
GTPL10715

> <PUBCHEM_XREF_EXT_ID>
10715

> <PUBCHEM_PUBMED_ID>
32633831
32275812
32284326
32660307
28124907
29511076
28659436
32004427

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715

> <PUBCHEM_CID_ASSOCIATIONS>
121304016  1

$$$$
405067338
  -OEChem-02172115172D

 32 34  0     1  0  0  0  0  0999 V2000
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0  0  0  0
  2  3  1  0  0  0  0
  3  4  1  0  0  0  0
  4  5  1  0  0  0  0
  5  6  1  0  0  0  0
  6  7  1  0  0  0  0
  7  8  1  0  0  0  0
  8  9  1  0  0  0  0
  3  9  1  0  0  0  0
  2 10  1  0  0  0  0
 10 11  1  0  0  0  0
 11 12  1  0  0  0  0
 11 13  1  0  0  0  0
 13 14  2  0  0  0  0
 13 15  1  0  0  0  0
 15 16  2  0  0  0  0
 15 17  1  0  0  0  0
 17 18  1  0  0  0  0
 18 19  2  0  0  0  0
 19 20  1  0  0  0  0
 20 21  1  0  0  0  0
 21 22  1  0  0  0  0
 22 23  1  0  0  0  0
 22 24  1  0  0  0  0
 19 24  1  0  0  0  0
 24 25  1  0  0  0  0
 22 26  1  0  0  0  0
 11 27  1  0  0  0  0
 27 28  1  0  0  0  0
 28 29  1  0  0  0  0
 29 30  1  0  0  0  0
 30 31  1  0  0  0  0
 31 32  1  0  0  0  0
 27 32  1  0  0  0  0
M  END
> <PUBCHEM_COMPOUND_ID_TYPE>
0

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_SUBSTANCE_ID>
405067338

> <PUBCHEM_SUBSTANCE_VERSION>
2

> <PUBCHEM_EXT_DATASOURCE_NAME>
IUPHAR-DB

> <PUBCHEM_EXT_DATASOURCE_REGID>
10747

> <PUBCHEM_SUBSTANCE_COMMENT>
IUPHAR/BPS Guide to Pharmacology (GtoPdb) Comment: ONO-5334 is a cysteine protease inhibitor with activity against cathepsin K. It was an oral drug lead that was considered as a bone resorption inhibitor for the treatment of postmenopausal osteoporosis.  ONO-5334 has some antiviral activity against SARS-CoV-2, and antagonises viral replication in human iPSC-derived pneumocyte-like cells .
Clinical use: ONO-5334 was progressed to Phase 2 clinical evaluation and has completed a trial in osteoporosis and osteopenia.

> <PUBCHEM_SUBSTANCE_SYNONYM>
ONO-5334
N-[(1S)-3-[(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazinyl]-1-(oxan-4-yl)-2,3-dioxopropyl]cycloheptanecarboxamide
ONO 5334
ONO5334
GTPL10747

> <PUBCHEM_XREF_EXT_ID>
10747

> <PUBCHEM_EXT_DATASOURCE_URL>
http://www.guidetopharmacology.org

> <PUBCHEM_EXT_SUBSTANCE_URL>
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10747

> <PUBCHEM_CID_ASSOCIATIONS>
68719553  1

$$$$
